Clinical Trials: Biologics

The 794 clinical trials listed here include 419 that have not yet started recruiting patients or are just now seeking volunteers to participate and another 375 that are active, but not recruiting new patients. This information is potentially valuable to patients still seeking effective treatments for hundreds of diseases, including autoimmune disorders, cancer, cardiovascular diseases, diabetes, infectious diseases, neurological disorders, and many more. It provides a new therapeutic option to discuss with physicians. Those interested in obtaining more information about certain clinical trials can use the URL code listed for each trial to log onto [www.clinicaltrials.gov](http://www.clinicaltrials.gov), the clinical tests database of the National Institutes of Health.

<table>
<thead>
<tr>
<th>Category</th>
<th>Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune Disorders</td>
<td>39</td>
</tr>
<tr>
<td>Blood Disorders</td>
<td>34</td>
</tr>
<tr>
<td>Cancer</td>
<td>384</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td>34</td>
</tr>
<tr>
<td>Diabetes</td>
<td>5</td>
</tr>
<tr>
<td>Digestive Disorders</td>
<td>18</td>
</tr>
<tr>
<td>Eye Disorders</td>
<td>14</td>
</tr>
<tr>
<td>Genetic Disorders</td>
<td>16</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>122</td>
</tr>
<tr>
<td>Musculoskeletal Disorders</td>
<td>33</td>
</tr>
<tr>
<td>Neurological Disorders</td>
<td>18</td>
</tr>
<tr>
<td>Respiratory Diseases</td>
<td>8</td>
</tr>
<tr>
<td>Skin Diseases115</td>
<td>15</td>
</tr>
<tr>
<td>Transplantation</td>
<td>5</td>
</tr>
<tr>
<td>Others</td>
<td>49</td>
</tr>
</tbody>
</table>
Source: www.clinicaltrials.gov; Search criteria: Biological, Phase 0, 1, 2, 3; industry only, United States. Included are only active clinical trials – active, not recruiting; recruiting, not yet recruiting, and enrolling by invitation. Search performed 2/5/2013.
Autoimmune disorders – 39 Active Clinical Trials
— Psoriasis is listed under Skin Disorders —

Study 1 – Recruiting
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Multiple Sclerosis, Secondary Progressive
http://ClinicalTrials.gov/show/NCT01684761

Study 2 – Active, not recruiting
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
Scleroderma
http://ClinicalTrials.gov/show/NCT00946699

Study 3 – Recruiting
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01526057

Study 4 – Active, not recruiting
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
http://ClinicalTrials.gov/show/NCT00050778

Study 5 – Active, not recruiting
An Efficacy and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis (RA) Despite Treatment With Methotrexate, Non Steroidal Pain Medications and/or Corticosteroids
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT00973479

Study 6 – Recruiting
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
http://ClinicalTrials.gov/show/NCT01484496

Study 7 – Active, not recruiting
Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01559103

Study 8 – Active, not recruiting
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01373151

Study 9 – Recruiting
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
Systemic Lupus Erythematosus
http://ClinicalTrials.gov/show/NCT01405196

Study 10 – Recruiting
Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01359943
Study 11 – Active, not recruiting
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Multiple Sclerosis, Relapsing-Remitting
http://ClinicalTrials.gov/show/NCT00930553

Study 12 – Recruiting
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Lupus Nephritis | Systemic Lupus Erythematosus
http://ClinicalTrials.gov/show/NCT01639339

Study 13 – Recruiting
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
Juvenile Idiopathic Arthritis
http://ClinicalTrials.gov/show/NCT01230827

Study 14 – Active, not recruiting
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Systemic Lupus Erythematosus
http://ClinicalTrials.gov/show/NCT00724867

Study 15 – Active, not recruiting
A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01712178
Study 16 – Recruiting
A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
http://ClinicalTrials.gov/show/NCT01438489

Study 17 – Recruiting
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01519791

Study 18 – Active, not recruiting
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
Juvenile Idiopathic Arthritis
http://ClinicalTrials.gov/show/NCT01777399

Study 19 – Recruiting
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFα Biologics
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01636817

Study 20 – Recruiting
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
Idiopathic Thrombocytopenic Purpura
http://ClinicalTrials.gov/show/NCT00547066
Study 21 – Active, not recruiting
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis, Relapsing Remitting
http://ClinicalTrials.gov/show/NCT01462318

Study 22 – Recruiting
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
http://ClinicalTrials.gov/show/NCT01585766

Study 23 – Active, not recruiting
Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Respond Poorly to Anti-TNFα Therapies
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT00468546

Study 24 – Active, not recruiting
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01261403

Study 25 – Active, not recruiting
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01296711
Study 26 – Recruiting
IGIV Study for Chronic ITP Patients Ages 3-70
Idiopathic Thrombocytopenic Purpura
http://ClinicalTrials.gov/show/NCT00511147

Study 27 – Recruiting
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura
Idiopathic Thrombocytopenic Purpura
http://ClinicalTrials.gov/show/NCT01071954

Study 28 – Recruiting
Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01752855
Study 29 – Active, not recruiting
A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
Systemic Lupus Erythematosus
http://ClinicalTrials.gov/show/NCT00583362

Study 30 – Active, not recruiting
Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
http://ClinicalTrials.gov/show/NCT01440192

Study 31 – Not yet recruiting
The Evaluation of Belimumab in Myasthenia Gravis (MG)
Myasthenia Gravis
http://ClinicalTrials.gov/show/NCT01480596

Study 32 – Active, not recruiting
Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT00425932

Study 33 – Recruiting
Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage
Rheumatoid Arthritis
http://ClinicalTrials.gov/show/NCT01333878

Study 34 – Recruiting
Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

http://ClinicalTrials.gov/show/NCT01351480

Study 35 – Recruiting
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Rheumatoid Arthritis

http://ClinicalTrials.gov/show/NCT01636843
Study 36 – Recruiting
Interventional Study in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
**Idiopathic Thrombocytopenic Purpura**
[http://ClinicalTrials.gov/show/NCT01143038](http://ClinicalTrials.gov/show/NCT01143038)

Study 37 – Recruiting
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
**Rheumatoid Arthritis**
[http://ClinicalTrials.gov/show/NCT01377012](http://ClinicalTrials.gov/show/NCT01377012)

Study 38 – Recruiting
Balancing Lupus Experiences With Stress Strategies
**Systemic Lupus Erythematosus**
[http://ClinicalTrials.gov/show/NCT01351662](http://ClinicalTrials.gov/show/NCT01351662)

Study 39 – Active, not recruiting
Abatacept Versus Adalimumab Head-to-Head
**Rheumatoid Arthritis**
[http://ClinicalTrials.gov/show/NCT00929864](http://ClinicalTrials.gov/show/NCT00929864)

**Blood Disorders – 34 Active Clinical Trials**

Study 1 – Active, not recruiting
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
**Hemophilia A**
[http://ClinicalTrials.gov/show/NCT01029340](http://ClinicalTrials.gov/show/NCT01029340)
Study 2 – Active, not recruiting
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
Hemophilia B
http://ClinicalTrials.gov/show/NCT00768287

Study 3 – Recruiting
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Hemophilia A
http://ClinicalTrials.gov/show/NCT01619046
Study 4 – Recruiting
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Anemia
http://ClinicalTrials.gov/show/NCT01146574

Study 5 – Active, not recruiting
An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
Reversal of Coagulopathy
http://ClinicalTrials.gov/show/NCT00803101

Study 6 – Recruiting
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic Thrombocytopenic Purpura
http://ClinicalTrials.gov/show/NCT01151423

Study 7 – Not yet recruiting
Belimumab in Remission of VASculitis
Vasculitis
http://ClinicalTrials.gov/show/NCT01663623

Study 8 – Recruiting
Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII
Hemophilia A
http://ClinicalTrials.gov/show/NCT00543439
Study 9 – Active, not recruiting
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment Hemophilia A
http://ClinicalTrials.gov/show/NCT00623480

Study 10 – Not yet recruiting
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen
Hemophilia A or B With Factor VIII (FVIII) or Factor IX (FIX) Inhibitors
http://ClinicalTrials.gov/show/NCT01757405
Study 11 – Recruiting
A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S 303 Treated Red Blood Cells
Focus: Assess Post Infusion Viability of S303 RBCs
http://ClinicalTrials.gov/show/NCT01711346

Study 12 – Recruiting
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests
Reversal of Blood Thinner Use in Healthy Volunteers
http://ClinicalTrials.gov/show/NCT01758432

Study 13 – Recruiting
Babesia Testing in Blood Donors
Transfusion Transmitted Babesiosis
http://ClinicalTrials.gov/show/NCT01528449

Study 14 – Recruiting
Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B
Hemophilia B
http://ClinicalTrials.gov/show/NCT01335061

Study 15 – Recruiting
Pragmatic, Randomized Optimal Platelets and Plasma Ratios
Trauma
http://ClinicalTrials.gov/show/NCT01545232

Study 16 – Recruiting
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

**Hemophilia A**

[http://ClinicalTrials.gov/show/NCT01486927](http://ClinicalTrials.gov/show/NCT01486927)

Study 17 – Recruiting

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

**Hemophilia B**

[http://ClinicalTrials.gov/show/NCT01496274](http://ClinicalTrials.gov/show/NCT01496274)

Study 18 – Recruiting

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

**Hemophilia A**

[http://ClinicalTrials.gov/show/NCT01580293](http://ClinicalTrials.gov/show/NCT01580293)

Study 19 – Recruiting

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

**Hemophilia A**

[http://ClinicalTrials.gov/show/NCT01178294](http://ClinicalTrials.gov/show/NCT01178294)

Study 20 – Recruiting

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

**Von Willebrand Disease**

[http://ClinicalTrials.gov/show/NCT01410227](http://ClinicalTrials.gov/show/NCT01410227)

Study 21 – Active, not recruiting

Early Prophylaxis Immunologic Challenge (EPIC) Study
Hemophilia A

http://ClinicalTrials.gov/show/NCT01376700

Study 22 – Not yet recruiting
Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

http://ClinicalTrials.gov/show/NCT01775618

Study 23 – Active, not recruiting
TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

http://ClinicalTrials.gov/show/NCT01192022

Study 24 – Recruiting
BAY81-8973 Pediatric Safety and Efficacy Trial

http://ClinicalTrials.gov/show/NCT01311648

Study 25 – Recruiting
Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery

http://ClinicalTrials.gov/show/NCT01662856

Study 26 – Recruiting
Phase 3 Study of Fibrocaps™ in Surgical Bleeding

http://ClinicalTrials.gov/show/NCT01527357

Study 27 – Recruiting
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease Anemia, Chronic Kidney Disease
http://ClinicalTrials.gov/show/NCT01652872

Study 28 – Recruiting
Wilate in Subjects With Von Willebrand Disease Who Undergo Major Surgery Prevent Bleeding in Major Surgery
http://ClinicalTrials.gov/show/NCT01365546

Study 29 – Recruiting
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
Hemophilia B
http://ClinicalTrials.gov/show/NCT01687608

Study 30 – Recruiting
Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries Soft Tissue Surgical Bleeding
http://ClinicalTrials.gov/show/NCT01731938

Study 31 – Recruiting
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
Hemophilia
http://ClinicalTrials.gov/show/NCT01708564

Study 32 – Active, not recruiting
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A
Hemophilia A
http://ClinicalTrials.gov/show/NCT01434511
Study 33 – Not yet recruiting
Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers
Coagulation Defects
http://ClinicalTrials.gov/show/NCT01589666

Study 34 – Recruiting
Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries
Parenchymous Tissue Surgical Bleeding
http://ClinicalTrials.gov/show/NCT01754480

Cancer – 385 Active Clinical Trials

Study 1 – recruiting
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
Prostate Cancer
http://ClinicalTrials.gov/show/NCT01048151

Study 2 – Recruiting
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Breast Cancer
http://ClinicalTrials.gov/show/NCT01220128

Study 3 – Active, not recruiting
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma
Pancreatic Cancer
Study 4 – Active, not recruiting
Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer
Renal Cell Carcinoma

Study 5 – Recruiting
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Melanoma

Study 6 – Active, not recruiting
Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia

Study 7 – Recruiting
Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
Acute Myeloid Leukemia
Study 8 – Recruiting
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
Neuroblastoma
http://ClinicalTrials.gov/show/NCT01592045

Study 9 – Recruiting
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Multiple Myeloma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01435720

Study 10 – Active, not recruiting
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01354431

Study 11 – Recruiting
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Melanoma
http://ClinicalTrials.gov/show/NCT01489059

Study 12 – Recruiting
A Study of IMC-RON8 in Advanced Solid Tumors
Cancer
http://ClinicalTrials.gov/show/NCT01119456

Study 13 – Recruiting
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01359657

Study 14 – Active, not recruiting
A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies Metastatic Castration-resistant Prostrate Cancer (mCRPC)|Renal Cell Carcinoma (RCC)|Metastatic Melanoma | Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00730639

Study 15 – Recruiting
Multiple Ascending Dose (MDX1105-01)
Cancer
http://ClinicalTrials.gov/show/NCT00729664

Study 16 – Active, not recruiting
Open Label Extension Study of Conatumumab (AMG 655)
Solid Tumors
http://ClinicalTrials.gov/show/NCT01327612

Study 17 – Active, not recruiting
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
Melanoma
http://ClinicalTrials.gov/show/NCT00003715

Study 18 – Active, not recruiting
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Breast Cancer
http://ClinicalTrials.gov/show/NCT00728949

Study 19 – Active, not recruiting
A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer
Prostate Cancer
http://ClinicalTrials.gov/show/NCT00629057

Study 20 – Active, not recruiting
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen
Prostate Cancer
http://ClinicalTrials.gov/show/NCT00715078

Study 21 – Recruiting
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01472081

Study 22 – Active, not recruiting
Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin’s Lymphoma
Lymphoma
http://ClinicalTrials.gov/show/NCT00017290

Study 23 – Recruiting
A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer
Prostate Cancer
http://ClinicalTrials.gov/show/NCT01322490

Study 24 – Active, not recruiting
Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin’s Lymphoma
Lymphoma
Study 25 – Recruiting
Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy
Epithelial Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01521143

Study 26 – Active, not recruiting
Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma
Melanoma
http://ClinicalTrials.gov/show/NCT00010309

Study 27 – Active, not recruiting
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Melanoma
http://ClinicalTrials.gov/show/NCT00004025

Study 28 – Recruiting
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in First-Line or in Switch Maintenance in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01454102

Study 29 – Active, not recruiting
Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma
Melanoma
http://ClinicalTrials.gov/show/NCT00769704
Study 30 – Recruiting
A Study in Second Line Metastatic Colorectal Cancer
Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01183780
Study 31 – Active, not recruiting
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00409188

Study 32 – Recruiting
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01335399

Study 33 – Recruiting
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
Squamous Cell Carcinoma of the Oral Cavity
http://ClinicalTrials.gov/show/NCT01265849

Study 34 – Recruiting
Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Prostate Cancer
http://ClinicalTrials.gov/show/NCT01487863

Study 35 – Recruiting
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin’s Lymphoma
Lymphoma
http://ClinicalTrials.gov/show/NCT00258336

Study 36 – Active, not recruiting
Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01504542

Study 37 – Active, not recruiting
Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome
Myelodysplastic Syndromes
http://ClinicalTrials.gov/show/NCT00513578

Study 38 – Active, not recruiting
Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas
Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT00003780

Study 39 – Recruiting
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Prostate Cancer
http://ClinicalTrials.gov/show/NCT00925600

Study 40 – Recruiting
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Breast Cancer
http://ClinicalTrials.gov/show/NCT01234402

Study 41 – Active, not recruiting
Phase 2 Safety & Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 vs FOLFIRI in KRAS-mutant Metastatic Colorectal Carcinoma

Colorectal Cancer

http://ClinicalTrials.gov/show/NCT00813605

Study 42 – Recruiting
Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT00062907

Study 43 – Recruiting
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT00874107

Study 44 – Recruiting
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

Breast Cancer

http://ClinicalTrials.gov/show/NCT01516307

Study 45 – Recruiting
Trial of a Single ProHema-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies

Hematologic Malignancies

http://ClinicalTrials.gov/show/NCT01627314
Study 46 – Recruiting
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Cervical Intraepithelial Neoplasia
http://ClinicalTrials.gov/show/NCT01304524

Study 47 – Active, not recruiting
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00480025

Study 48 – Active, not recruiting
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00762034

Study 49 – Active, not recruiting
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
http://ClinicalTrials.gov/show/NCT00401843

Study 50 – Recruiting
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
HER2-Negative Breast Cancer
http://ClinicalTrials.gov/show/NCT01479244

Study 51 – Recruiting
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
Hepatocellular Carcinoma
http://ClinicalTrials.gov/show/NCT01140347

Study 52– Active, not recruiting
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00874848
Study 53 – Active, not recruiting
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme
http://ClinicalTrials.gov/show/NCT01280552

Study 54 – Active, not recruiting
Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin’s Lymphoma
Lymphoma
http://ClinicalTrials.gov/show/NCT00071955

Study 55 – Active, not recruiting
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin’s Lymphoma
Lymphoma
http://ClinicalTrials.gov/show/NCT00005959

Study 56 – Recruiting
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Small Cell Lung Carcinoma
http://ClinicalTrials.gov/show/NCT01450761

Study 57 – Recruiting
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder, Urethra, Ureter, or Renal Pelvis Carcinoma
Carcinoma of Urinary Tract | Urethral Carcinoma | Carcinoma of Ureter | Carcinoma of Renal Pelvis
http://ClinicalTrials.gov/show/NCT01282463

Study 58 – Active, not recruiting
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse

Lymphoma

http://ClinicalTrials.gov/show/NCT00069966

Study 59 – Active, not recruiting

Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

http://ClinicalTrials.gov/show/NCT00002767
Study 60 – Active, not recruiting
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission
Leukemia
http://ClinicalTrials.gov/show/NCT00454168

Study 61 – Recruiting
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Prostate Cancer
http://ClinicalTrials.gov/show/NCT01436968

Study 62 – Recruiting
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Melanoma
http://ClinicalTrials.gov/show/NCT01546571

Study 63 – Active, not recruiting
A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver
Hepatocellular Carcinoma
http://ClinicalTrials.gov/show/NCT00906373

Study 64 – Active, not recruiting
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
http://ClinicalTrials.gov/show/NCT00104780

Study 65 – Recruiting
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Lymphoma, Follicular

http://ClinicalTrials.gov/show/NCT01200589

Study 66 – Active, not recruiting
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Melanoma

http://ClinicalTrials.gov/show/NCT01515189

Study 67 – Active, not recruiting
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Sarcoma

http://ClinicalTrials.gov/show/NCT01141491

Study 68 – Active, not recruiting
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Bladder Cancer

http://ClinicalTrials.gov/show/NCT01200992

Study 69 – Active, not recruiting
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01471197

Study 70 – Recruiting
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Solid Tumors
http://ClinicalTrials.gov/show/NCT01629758

Study 71 – Recruiting
A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer
Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01111604

Study 72 – Active, not recruiting
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
Malignant Solid Tumor | Lymphomas | Multiple Myeloma
http://ClinicalTrials.gov/show/NCT00725634

Study 73 – Recruiting
Multiple Ascending Dose
Hepatocellular Carcinoma
http://ClinicalTrials.gov/show/NCT01658878

Study 74 – Recruiting
Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer
Recurrent Neuroendocrine Carcinoma of the Skin
http://ClinicalTrials.gov/show/NCT01440816

Study 75 – Active, not recruiting
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
Kidney Cancer
http://ClinicalTrials.gov/show/NCT00003181

Study 76 – Active, not recruiting
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
Resectable Pancreatic Adenocarcinoma
http://ClinicalTrials.gov/show/NCT00600002

Study 77 – Active, not recruiting
A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT01608711

Study 78 – Active, not recruiting
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Leukemia
http://ClinicalTrials.gov/show/NCT00024440

Study 79 – Recruiting
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Solid Tumors
http://ClinicalTrials.gov/show/NCT01061840

Study 80 – Active, not recruiting
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
Prostate Cancer
http://ClinicalTrials.gov/show/NCT00514072

Study 81 – Recruiting
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Acute Myeloid Leukemia
Study 82 – Recruiting
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Glioblastoma

http://ClinicalTrials.gov/show/NCT01478074

Study 83 – Active, not recruiting
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

Renal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01403285

Study 84 – Recruiting
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Metastatic Melanoma

http://ClinicalTrials.gov/show/NCT01621490

Study 85 – Active, not recruiting
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Metastatic Melanoma

http://ClinicalTrials.gov/show/NCT01335009

Study 86 – Active, not recruiting
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

Melanoma

http://ClinicalTrials.gov/show/NCT00815607

Study 87 – Recruiting
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Liver Cancer
http://ClinicalTrials.gov/show/NCT01387555

Study 88 – Recruiting
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01309126

Study 89 – Recruiting
Vaccine Therapy in Treating Patients With Breast Cancer
Breast Cancer
http://ClinicalTrials.gov/show/NCT00524277

Study 90 – Recruiting
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Lymphoma
http://ClinicalTrials.gov/show/NCT00989586

Study 91 – Recruiting
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
Melanoma
http://ClinicalTrials.gov/show/NCT01176461

Study 92 – Active, not recruiting
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Colorectal Cancer
http://ClinicalTrials.gov/show/NCT00522665

Study 93 – Active, not recruiting
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 Antibody BMS936558

Melanoma
http://ClinicalTrials.gov/show/NCT01176474

Study 94 – Active, not recruiting
Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer

Prostate Cancer
http://ClinicalTrials.gov/show/NCT00779402

Study 95 – Recruiting
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization

Melanoma
http://ClinicalTrials.gov/show/NCT00338377

Study 96 – Active, not recruiting
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer

Breast Cancer
http://ClinicalTrials.gov/show/NCT00068341

Study 97 – Active, not recruiting
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Brain and Central Nervous System Tumors
http://ClinicalTrials.gov/show/NCT00895180
Study 98 – Recruiting
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Melanoma

http://ClinicalTrials.gov/show/NCT01350401
Study 99 – Not yet recruiting
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
Acute Myelogenous Leukemia
http://ClinicalTrials.gov/show/NCT01639456

Study 100 – Active, not recruiting
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
Astrocytoma | Oligo-Astrocytoma | Glioma
http://ClinicalTrials.gov/show/NCT00795457

Study 101 – Active, not recruiting
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100/MART Melanoma
http://ClinicalTrials.gov/show/NCT01008527

Study 102 – Recruiting
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT01361711

Study 103 – Active, not recruiting
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL Leukemia
http://ClinicalTrials.gov/show/NCT00858117

Study 104 – Recruiting
Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Leukemia | Multiple Myeloma | Myelodysplastic Syndrome | Non-Hodgkin’s Lymphoma
http://ClinicalTrials.gov/show/NCT01746849

Study 105 – Recruiting
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients
Melanoma
http://ClinicalTrials.gov/show/NCT01585350

Study 106 – Recruiting
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
Prostate Cancer
http://ClinicalTrials.gov/show/NCT01706458

Study 107 – Active, not recruiting
Gene Therapy for Pleural Malignancies
Pleural Mesothelioma | Metastatic Pleural Effusions
http://ClinicalTrials.gov/show/NCT00299962

Study 108 – Recruiting
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Non-Hodgkin’s Lymphoma | Multiple Myeloma | Acute Myeloid Leukemia | Hodgkin Lymphoma |
Chronic Lymphocytic Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndrome
http://ClinicalTrials.gov/show/NCT00709592

Study 109 – Active, not recruiting
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

**Neuroendocrine Tumors**

http://ClinicalTrials.gov/show/NCT00314925

Study 110 – Recruiting
Recombinant Vaccinia Virus Administered Intravenously Followed by Intratumoral Boosts in Patients With Metastatic, Refractory Colorectal Carcinoma

**Colorectal Carcinoma**

http://ClinicalTrials.gov/show/NCT01394939

Study 111 – Recruiting
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma

**Unresectable Stage III or IV Melanoma**

http://ClinicalTrials.gov/show/NCT01397708

Study 112 – Recruiting
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

**Head and Neck Squamous Cell Carcinoma**

http://ClinicalTrials.gov/show/NCT01602315

Study 113 – Recruiting
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

**Multiple Myeloma**

http://ClinicalTrials.gov/show/NCT01602224

Study 114 – Active, not recruiting
Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer
[http://ClinicalTrials.gov/show/NCT01416038](http://ClinicalTrials.gov/show/NCT01416038)

Study 115 – Active, not recruiting
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
[http://ClinicalTrials.gov/show/NCT00030641](http://ClinicalTrials.gov/show/NCT00030641)

Study 116 – Recruiting
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Post-remission Chemotherapy for Leukemia
Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplasia
[http://ClinicalTrials.gov/show/NCT01297543](http://ClinicalTrials.gov/show/NCT01297543)

Study 117 – Active, not recruiting
Ph I/II Ipilimumab Vemurafenib Combo
Melanoma
[http://ClinicalTrials.gov/show/NCT01400451](http://ClinicalTrials.gov/show/NCT01400451)

Study 118 – Active, not recruiting
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Advanced Malignancies
[http://ClinicalTrials.gov/show/NCT00948961](http://ClinicalTrials.gov/show/NCT00948961)

Study 119 – Active, not recruiting
Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer
Pancreatic Cancer
[http://ClinicalTrials.gov/show/NCT00603863](http://ClinicalTrials.gov/show/NCT00603863)
Study 120 – Active, not recruiting
A Study of IMC-3G3 in Soft Tissue Sarcoma
Soft Tissue Sarcoma
http://ClinicalTrials.gov/show/NCT01185964

Study 121 – Recruiting
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
Chronic Lymphocytic Lymphoma
http://ClinicalTrials.gov/show/NCT00603668
Study 122 – Recruiting
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Transitional Cell Carcinoma of Bladder | Urethra Cancer | Ureter Cancer | Malignant Tumor of Renal Pelvis
http://ClinicalTrials.gov/show/NCT01326871

Study 123 – Recruiting
A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma
Malignant Glioma
http://ClinicalTrials.gov/show/NCT01156584

Study 124 – recruiting
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Non-Hodgkin Lymphoma | Chronic Lymphocytic Lymphoma
http://ClinicalTrials.gov/show/NCT00546793

Study 125 – Recruiting
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
Ovarian Cancer
http://ClinicalTrials.gov/show/NCT00660101

Study 126 – Recruiting
A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases
T-cell Lymphomas | T-cell Leukemia | Sezary Syndrome | Mycosis Fungoides
http://ClinicalTrials.gov/show/NCT00611208

Study 127 – Not yet recruiting
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Lymphoma
http://ClinicalTrials.gov/show/NCT01744223

Study 128 – Recruiting
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer
http://ClinicalTrials.gov/show/NCT01625260

Study 129 – Active, not recruiting
Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
Colon Cancer | Lung Cancer | Breast Cancer
http://ClinicalTrials.gov/show/NCT01147965

Study 130 – Active, not recruiting
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
Prostate Cancer
http://ClinicalTrials.gov/show/NCT00003183

Study 131 – Active, not recruiting
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT0098105

Study 132 – Active, not recruiting
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
http://ClinicalTrials.gov/show/NCT00689507

Study 133 – Recruiting
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01478048

Study 134 – Active, not recruiting
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Hematologic Cancer

http://ClinicalTrials.gov/show/NCT00742560

Study 135 – Active, not recruiting
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Bone Metastases in Subjects With Advanced Breast Cancer

http://ClinicalTrials.gov/show/NCT00321464

Study 136 – Enrolling by invitation
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01393964
Study 137 – Active, not recruiting
A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Participants Who Received Prior First Line Platinum Based Chemotherapy
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01168973

Study 138 – Recruiting
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Smoldering Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01441973

Study 139 – Recruiting
Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC
Metastatic Clear-cell Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01668784

Study 140 – Active, not recruiting
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01239797

Study 141 – Recruiting
Clinical Study of WT2725 in Patients With Advanced Solid Malignancies
Cancer
http://ClinicalTrials.gov/show/NCT01621542

Study 142 – Recruiting
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
Acute Myeloid Leukemia
http://ClinicalTrials.gov/show/NCT01632852

Study 143 – Recruiting
A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
Solid Tumors
http://ClinicalTrials.gov/show/NCT01608867

Study 144 – Recruiting
Safety Study of MGAH22 in HER2-positive Carcinomas
Breast Cancer | Gastric Cancer | Bladder Cancer | Ovarian Cancer | Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01148849
Study 145 – Recruiting
A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01300858

Study 146 – Active, not recruiting
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01265901

Study 147 – Active, not recruiting
A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00918203

Study 148 – Active, not recruiting
Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer
Prostate Cancer
http://ClinicalTrials.gov/show/NCT00715104

Study 149 – Recruiting
Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Squamous Cell Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01642004

Study 150 – Recruiting
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Cutaneous T-Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01728805

Study 151 – Recruiting
A Study of Ramucirumab and Paclitaxel in Patients With Solid Tumors
Malignant Solid Tumors
http://ClinicalTrials.gov/show/NCT01515306

Study 152 – Active, not recruiting
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00676507

Study 153 – Active, not recruiting
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
http://ClinicalTrials.gov/show/NCT01258608

Study 154 – Active, not recruiting
Ovarian Cancer Vaccine for Patients in Remission
Epithelial Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01068509

Study 155 – Active, not recruiting
A Study of IMC-A12 in Islet Cell Cancer
Carcinoma | Neuroendocrine Tumors
http://ClinicalTrials.gov/show/NCT00781911

Study 156 – Active, not recruiting
A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma

Melanoma
http://ClinicalTrials.gov/show/NCT00925314

Study 157 – Active, not recruiting
Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer
http://ClinicalTrials.gov/show/NCT00006215

Study 158 – Active, not recruiting
A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung

Adenocarcinoma of the Lung
http://ClinicalTrials.gov/show/NCT01218516

Study 159 – Active, not recruiting
Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-refractory Prostate Cancer

Bone Metastases
http://ClinicalTrials.gov/show/NCT00321620
Study 160 – Active, not recruiting
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
Kidney Cancer
http://ClinicalTrials.gov/show/NCT00087022

Study 161 – Recruiting
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Urothelial Carcinoma
http://ClinicalTrials.gov/show/NCT01353222

Study 162 – Active, not recruiting
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Chronic Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT01520922

Study 163 – Active, not recruiting
Idiotype Vaccine for Low-Grade Non-Hodgkin’s Lymphoma
Low-Grade Lymphoma
http://ClinicalTrials.gov/show/NCT00036426

Study 164 – Active, not recruiting
Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
Colorectal Cancer
http://ClinicalTrials.gov/show/NCT00062426

Study 165 – Active, not recruiting
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Breast Cancer
Study 166 – Active, not recruiting  
Denileukin Diftitox in Treating Patients With Non-Hodgkin’s Lymphoma  
Non-Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT00026429

Study 167 – Active, not recruiting  
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study  
Epithelial Ovarian Cancer

http://ClinicalTrials.gov/show/NCT01617629
Study 168 – Active, not recruiting
Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin’s Lymphoma
Non-Hodgkin’s Lymphoma
http://ClinicalTrials.gov/show/NCT00041730

Study 169 – Active, not recruiting
Vaccine Therapy for Patients With Stage III Melanoma
Malignant Melanoma
http://ClinicalTrials.gov/show/NCT00052130

Study 170 – Active, not recruiting
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Cancer | Solid Tumors
http://ClinicalTrials.gov/show/NCT01017731

Study 171 – Active, not recruiting
A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)
Acute Myelogenous Leukemia
http://ClinicalTrials.gov/show/NCT00510133

Study 172 – Active, not recruiting
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Waldenstrom Macroglobulinaemia
http://ClinicalTrials.gov/show/NCT00811733

Study 173 – Active, not recruiting
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Breast Cancer
http://ClinicalTrials.gov/show/NCT01427933
Study 174 – Active, not recruiting
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
Fallopian Tube Cancer | Ovarian Cancer | Primary Peritoneal Cavity Cancer
http://ClinicalTrials.gov/show/NCT00003634

Study 175 – Active, not recruiting
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
Metastatic Melanoma
http://ClinicalTrials.gov/show/NCT00039234

Study 176 – Active, not recruiting
Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer
Kidney Cancer
http://ClinicalTrials.gov/show/NCT00656734

Study 177 – Active, not recruiting
A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer
Ovarian Neoplasms
http://ClinicalTrials.gov/show/NCT00913835

Study 178 – Recruiting
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Leukemia | Lymphoma | Multiple Myeloma | Plasma Cell Neoplasm | Myelodysplastic Syndromes
Study 179 – Active, not recruiting
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Breast Cancer

http://ClinicalTrials.gov/show/NCT00490139

Study 180 – Active, not recruiting
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Squamous Cell Carcinoma of the Head and Neck

http://ClinicalTrials.gov/show/NCT01166542

Study 181 – Recruiting
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01160744

Study 182 – Active, not recruiting
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
Leukemia

http://ClinicalTrials.gov/show/NCT00006045
Study 183 – Active, not recruiting
Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia
Cervical Intraepithelial Neoplasia
http://ClinicalTrials.gov/show/NCT00493545

Study 184 – Recruiting
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
Cervical Intraepithelial Neoplasia
http://ClinicalTrials.gov/show/NCT01116245

Study 185 – Recruiting
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
Solid Tumors
http://ClinicalTrials.gov/show/NCT01577745

Study 186 – Recruiting
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Malignant Melanoma
http://ClinicalTrials.gov/show/NCT01696045

Study 187 – Recruiting
A Study to Compare BMS-936558 to the Physician’s Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy
Metastatic Melanoma
http://ClinicalTrials.gov/show/NCT01721746

Study 188 – Active, not recruiting
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

Ovarian Neoplasms | Breast Neoplasms | Prostatic Neoplasms

http://ClinicalTrials.gov/show/NCT01095848

Study 189 – Active, not recruiting
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

http://ClinicalTrials.gov/show/NCT00017550

Study 190 – Active, not recruiting
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer

Pancreas Cancer

http://ClinicalTrials.gov/show/NCT00300950

Study 191 – Recruiting
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Malignant Melanoma

http://ClinicalTrials.gov/show/NCT01227551

Study 192 – Recruiting
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Melanoma

http://ClinicalTrials.gov/show/NCT01673854
Study 193 – Active, not recruiting
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
Bladder Cancer
http://ClinicalTrials.gov/show/NCT00109655

Study 194 – Recruiting
A Study to Assess the Pharmacokinetics of Ramucirumab in Combination With FOLFIRI Solid Tumors
http://ClinicalTrials.gov/show/NCT01634555

Study 195 – Active, not recruiting
Vaccine Therapy for Patients With Stage IV Melanoma Malignant Melanoma
http://ClinicalTrials.gov/show/NCT00052156

Study 196 – Active, not recruiting
Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer Head and Neck Cancer
http://ClinicalTrials.gov/show/NCT00003257

Study 197 – Active, not recruiting
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter
http://ClinicalTrials.gov/show/NCT00005958

Study 198 – Recruiting
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Patients Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01611558

Study 199 – Active, not recruiting
Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
Bone Metastases
http://ClinicalTrials.gov/show/NCT00330759

Study 200 – Active, not recruiting
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Prostate Cancer
http://ClinicalTrials.gov/show/NCT00005960

Study 201 – Active, not recruiting
PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen
Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT00088660

Study 202 – Active, not recruiting
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Stomach Cancer | Esophageal Cancer
http://ClinicalTrials.gov/show/NCT01246960

Study 203 – Active, not recruiting
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Recurrent Ovarian Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma
http://ClinicalTrials.gov/show/NCT01381861

Study 204 – Active, not recruiting
Study of Ramucirumab in Ovarian Cancer
Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma
http://ClinicalTrials.gov/show/NCT00721162

Study 205 – Active, not recruiting
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
Melanoma
http://ClinicalTrials.gov/show/NCT00942162

Study 206 – Active, not recruiting
A Study of Paclitaxel With or Without Ramucirumab in Metastatic Gastric Adenocarcinoma
Gastric Cancer
http://ClinicalTrials.gov/show/NCT01170663

Study 207 – Active, not recruiting
A Study of Ramucirumab and Docetaxel in Patients With Solid Tumors
Malignant Solid Tumors
http://ClinicalTrials.gov/show/NCT01567163

Study 208 – Active, not recruiting
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
Fallopian Tube Cancer | Ovarian Cancer | Primary Peritoneal Cavity Cancer
http://ClinicalTrials.gov/show/NCT00004064
Study 209 – Active, not recruiting
Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01159964

Study 210 – Recruiting
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
Oral Mucositis
http://ClinicalTrials.gov/show/NCT01403064

Study 211 – Recruiting
KW 0761 or Investigator’s Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Adult T-cell Leukemia-Lymphoma
http://ClinicalTrials.gov/show/NCT01626664

Study 212 – Recruiting
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Solid Tumors
http://ClinicalTrials.gov/show/NCT01624467

Study 213 – Recruiting
Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01673867
Study 214 – Recruiting
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Adenocarcinoma|Her2+|Advanced Metastatic Breast Cancer|Metastatic ErbB2|Invasive Breast
Advanced Breast Cancer
http://ClinicalTrials.gov/show/NCT00968968

Study 215 – Active, not recruiting
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
Metastatic Melanoma
http://ClinicalTrials.gov/show/NCT00395070

Study 216 – Recruiting
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
Non-Hodgkin's Lymphoma | Hodgkin Lymphoma | Multiple Myeloma | Chronic Myelogenous Leukemia
http://ClinicalTrials.gov/show/NCT01592370

Study 217 – Recruiting
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Metastatic Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01582672

Study 218 – Recruiting
Study of Patients With Advanced Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00948675

Study 219 – Recruiting
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

**Chronic Lymphocytic Leukemia**

[http://ClinicalTrials.gov/show/NCT01039376](http://ClinicalTrials.gov/show/NCT01039376)

Study 220 – Enrolling by invitation
An Extended Use Study of Safety and Efficacy of OncoVEXGM-CSF in Melanoma

**Melanoma**

[http://ClinicalTrials.gov/show/NCT01368276](http://ClinicalTrials.gov/show/NCT01368276)

Study 221 – Recruiting
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL)

**Non-Hodgkin Lymphoma**

[http://ClinicalTrials.gov/show/NCT01294579](http://ClinicalTrials.gov/show/NCT01294579)

Study 222 – Recruiting
Immunotherapy Study for Surgically Resected Pancreatic Cancer

**Pancreatic Cancer**

[http://ClinicalTrials.gov/show/NCT01072981](http://ClinicalTrials.gov/show/NCT01072981)

Study 223 – Active, not recruiting
Vaccine Therapy in Treating Patients With Malignant Melanoma

**Melanoma**

[http://ClinicalTrials.gov/show/NCT00128583](http://ClinicalTrials.gov/show/NCT00128583)

Study 224 – Active, not recruiting
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Patients With Gastric Cancer and Adenocarcinoma
Gastric Cancer | Adenocarcinoma
http://ClinicalTrials.gov/show/NCT00917384

Study 225 – Active, not recruiting
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Prostate Cancer
http://ClinicalTrials.gov/show/NCT00078585

Study 226 – Active, not recruiting
Vaccine Study for Surgically Resected Pancreatic Cancer
Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT00569387

Study 227 – Active, not recruiting
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
Leukemia
http://ClinicalTrials.gov/show/NCT00003991

Study 228 – Active, not recruiting
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
Metastatic Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT01272791

Study 229 – Active, not recruiting
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Prostatic Cancer
http://ClinicalTrials.gov/show/NCT01431391
Study 230 – Recruiting
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
http://ClinicalTrials.gov/show/NCT00998192

Study 231 – Active, not recruiting
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin’s Lymphoma Who Have Received Prior Treatment
Non-Hodgkin’s Lymphoma
http://ClinicalTrials.gov/show/NCT01007292

Study 232 – Recruiting
Study of ACE-041 in Patients With Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
http://ClinicalTrials.gov/show/NCT01458392

Study 233 – Recruiting
Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
Glioblastoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Anaplastic Oligoastrocytoma
http://ClinicalTrials.gov/show/NCT01470794

Study 234 – Active, not recruiting
Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
Advanced Solid Tumors | Multiple Myeloma
http://ClinicalTrials.gov/show/NCT00996957
Study 235 – Recruiting
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Locally Advanced Malignant Neoplasm | Malignant Solid Tumour
http://ClinicalTrials.gov/show/NCT01325558

Study 236 – Active, not recruiting
Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02)
Malignant Glioma
http://ClinicalTrials.gov/show/NCT00589875

Study 237 – Active, not recruiting
Open Label Extension In Cancer Patients
Neoplasms | Bone Metastases
http://ClinicalTrials.gov/show/NCT00830180

Study 238 – Recruiting
Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
Malignant Solid Tumors
http://ClinicalTrials.gov/show/NCT01765790

Study 239 – Active, not recruiting
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
Grade IV Glioma | Grade IV Astrocytoma | Glioblastoma Multiforme
http://ClinicalTrials.gov/show/NCT01290692
Study 240 – Recruiting
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
Solid Tumors
http://ClinicalTrials.gov/show/NCT01345201

Study 241 – Recruiting
A Study of IMC-TR1 in Patients With Advanced Solid Tumors
Solid Tumors
http://ClinicalTrials.gov/show/NCT01646203

Study 242 – Active, not recruiting
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01219010

Study 243 – Active, not recruiting
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT00638612

Study 244 – Recruiting
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
Solid Tumor Malignancies
http://ClinicalTrials.gov/show/NCT01118819

Study 245 – Recruiting
A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia
Hairy Cell Leukemia
Study 246 – Active, not recruiting
Study of REOLYSIN® in Combination With FOLFIRI in Patients With Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer
Colorectal Cancer

http://ClinicalTrials.gov/show/NCT00586924

Study 247 – Active, not recruiting
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
Non-Hodgkin's Lymphoma | Hodgkin's Disease | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Acute Lymphoblastic Leukemia

http://ClinicalTrials.gov/show/NCT01274624

Study 248 – Recruiting
Safety Study of MGA271 in Refractory Cancer
Prostate Cancer | Pancreatic Cancer | Melanoma | Renal Cell Carcinoma | Ovarian Cancer | Colorectal Cancer | Gastric Cancer | Bladder Cancer | Non-Small Cell Lung Cancer | Glioblastoma

http://ClinicalTrials.gov/show/NCT01527838

Study 249 – Recruiting
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Malignant Solid Tumors

http://ClinicalTrials.gov/show/NCT01391143

Study 250 – Active, not recruiting
Autologous Vaccine for Follicular Lymphoma
Follicular Lymphoma

http://ClinicalTrials.gov/show/NCT01022255
Study 251 – Recruiting
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors Neoplasms
http://ClinicalTrials.gov/show/NCT01346358

Study 252 – Recruiting
A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors Solid Tumors
http://ClinicalTrials.gov/show/NCT01603979

Study 253 – Recruiting
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
http://ClinicalTrials.gov/show/NCT01585987

Study 254 – Recruiting
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Neoplasms
http://ClinicalTrials.gov/show/NCT01288989

Study 255 – Recruiting
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer Ovarian Neoplasms
http://ClinicalTrials.gov/show/NCT01616303

Study 256 – Active, not recruiting
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01025206

Study 257 – Active, not recruiting
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

NY-ESO-1 Positive-Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01234012

Study 258 – Recruiting
Evaluation of TRC105 In The Treatment Of Recurrent Glioblastoma After Prior Antiangiogenic Therapy (Including Anti-VEGF Therapy)

Glioblastoma Multiforme
http://ClinicalTrials.gov/show/NCT01564914

Study 259 – Active, not recruiting
Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

Prostate Cancer
http://ClinicalTrials.gov/show/NCT00753220

Study 260 – Active, not recruiting
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma
http://ClinicalTrials.gov/show/NCT00998322
Study 261 – Active, not recruiting
Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
Brain and Central Nervous System Tumors
http://ClinicalTrials.gov/show/NCT00052624

Study 262 – Recruiting
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00861627

Study 263 – Recruiting
Sym004 in Patients With Advanced Solid Tumors
Metastatic Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01117428

Study 264 – Active, not recruiting
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Head and Neck Cancer
http://ClinicalTrials.gov/show/NCT00753038

Study 265 – Recruiting
Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab in Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT01644253
Study 266 – Recruiting
CNDO-109-AANK for AML in First Complete Remission (CR1)
Acute Myeloid Leukemia
http://ClinicalTrials.gov/show/NCT01520558

Study 267 – Active, not recruiting
Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma
Melanoma
http://ClinicalTrials.gov/show/NCT00016263

Study 268 – Recruiting
CRS-207 Cancer Vaccine in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
http://ClinicalTrials.gov/show/NCT01675765

Study 269 – Active, not recruiting
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
Malignant Gliomas
http://ClinicalTrials.gov/show/NCT00751270

Study 270 – Not yet recruiting
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01774578

Study 271 – Recruiting
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Hematological Malignancies | Leukemia | Lymphoma
http://ClinicalTrials.gov/show/NCT01474681

Study 272 – Recruiting
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01670994

Study 273 – Active, not recruiting
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00982111

Study 274 – Recruiting
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Mantle Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01437709

Study 275 – Active, not recruiting
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
http://ClinicalTrials.gov/show/NCT00017602

Study 276 – Active, not recruiting
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
Prostate Cancer
http://ClinicalTrials.gov/show/NCT01197209
Study 277 – Recruiting
Open Label Study to Evaluate the Safety and Tolerability of GI-6301 a Vaccine Consisting of Whole Heat-Killed Recombinant Yeast Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors
Solid Tumors
http://ClinicalTrials.gov/show/NCT01519817

Study 278 – Active, not recruiting
Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer
Solid Tumors
http://ClinicalTrials.gov/show/NCT00550927

Study 279 – Recruiting
Trial of Adjuvant FANG™ Vaccine for High Risk Stage IIIc Ovarian Cancer
Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01309230

Study 280 – Recruiting
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
Malignant Melanoma or Solid Tumors
http://ClinicalTrials.gov/show/NCT01239134

Study 281 – Active, not recruiting
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Leukemia | Lymphoma
http://ClinicalTrials.gov/show/NCT00551239

Study 282 – Recruiting
Salvage Ovarian FANG Vaccine + Bevacizumab

**Ovarian Cancer**

[http://ClinicalTrials.gov/show/NCT01551745](http://ClinicalTrials.gov/show/NCT01551745)

**Study 283 – Recruiting**

Safety Study of $^{212}$Pb-TCMC-Trastuzumab Radio Immunotherapy

**Breast Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasms | Pancreatic Neoplasms | Stomach Neoplasms**

[http://ClinicalTrials.gov/show/NCT01384253](http://ClinicalTrials.gov/show/NCT01384253)

**Study 284 – Recruiting**

Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer

**Advanced Cancer | Metastatic Cancer**

[http://ClinicalTrials.gov/show/NCT01505153](http://ClinicalTrials.gov/show/NCT01505153)

**Study 285 – Active, not recruiting**

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

**Non-Small Cell Lung Cancer**

[http://ClinicalTrials.gov/show/NCT00655161](http://ClinicalTrials.gov/show/NCT00655161)

**Study 286 – Recruiting**

Phase II FANG in Advanced Melanoma

**Advanced Melanoma**

[http://ClinicalTrials.gov/show/NCT01453361](http://ClinicalTrials.gov/show/NCT01453361)

**Study 287 – Not yet recruiting**

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
Melanoma

http://ClinicalTrials.gov/show/NCT01709162

Study 288 – Active, not recruiting
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma

http://ClinicalTrials.gov/show/NCT00014664

Study 289 – Recruiting
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Metastatic Melanoma

http://ClinicalTrials.gov/show/NCT00984464

Study 290 – Recruiting
Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases
Colon Cancer

http://ClinicalTrials.gov/show/NCT01505166

Study 291 – Recruiting
Monoclonal Antibody hA20 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
Lymphoma

http://ClinicalTrials.gov/show/NCT00112970

Study 292 – Recruiting
Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks
Melanoma
http://ClinicalTrials.gov/show/NCT01636882

Study 293 – Recruiting
Safety Study of Attenuated Vaccinia Virus (GL-ONC1) With Combination Therapy in Head & Neck Cancer
Head and Neck Cancer
http://ClinicalTrials.gov/show/NCT01584284

Study 294 – Active, not recruiting
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
Chronic Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT00772486

Study 295 – Recruiting
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Superficial Bladder Cancer
http://ClinicalTrials.gov/show/NCT00595088

Study 296 – Active, not recruiting
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
Leukemia
http://ClinicalTrials.gov/show/NCT00017589

Study 297 – Recruiting
Phase 1 Study of ONT-10 in Patients With Solid Tumors
Solid Tumors
http://ClinicalTrials.gov/show/NCT01556789

Study 298 – Active, not recruiting
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
Breast Cancer
http://ClinicalTrials.gov/show/NCT01152398

Study 299 – Active, not recruiting
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Gastrointestinal Carcinoid Tumor | Islet Cell Tumor | Lung Cancer | Neoplastic Syndrome | Neuroendocrine Tumor
http://ClinicalTrials.gov/show/NCT00227617

Study 300 – Active, not recruiting
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
http://ClinicalTrials.gov/show/NCT00983528

Study 301 – Active, not recruiting
Redirected Auto T Cells for Advanced Myeloma
Myeloma
http://ClinicalTrials.gov/show/NCT01352286
Study 302 – Recruiting
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Colorectal Cancer
http://ClinicalTrials.gov/show/NCT00940316

Study 303 – Active, not recruiting
Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
Lymphoma
http://ClinicalTrials.gov/show/NCT00057967

Study 304– Recruiting
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
Myeloma
http://ClinicalTrials.gov/show/NCT00698776

Study 305 – Active, not recruiting
Bevacizumab in Treating Patients With Angiosarcoma
Sarcoma
http://ClinicalTrials.gov/show/NCT00288015

Study 306 – Active, not recruiting
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Breast Cancer
http://ClinicalTrials.gov/show/NCT00654836

Study 307 – Active, not recruiting
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

Osteosarcoma

http://ClinicalTrials.gov/show/NCT00667342

Study 308 – Recruiting
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Metastatic Colorectal Cancer

http://ClinicalTrials.gov/show/NCT00803647

Study 309 – Active, not recruiting
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Breast Cancer

http://ClinicalTrials.gov/show/NCT00667251

Study 310 – Active, not recruiting
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM

Brain and Central Nervous System Tumors

http://ClinicalTrials.gov/show/NCT00905060

Study 311 – Recruiting
Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Nonmalignant Neoplasm

http://ClinicalTrials.gov/show/NCT00919503
Study 312 – Active, not recruiting
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Breast Cancer
http://ClinicalTrials.gov/show/NCT01423123

Study 313 – Recruiting
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01380145

Study 314 – Recruiting
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
Cancer Survivor | Human Papilloma Virus Infection
http://ClinicalTrials.gov/show/NCT01492582

Study 315 – Recruiting
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Stage IV Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01652196

Study 316 – Active, not recruiting
Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy
B-Cell Chronic Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT00800943

Study 317 – Recruiting
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Giant Cell Glioblastoma | Glioblastoma | Gliosarcoma

http://ClinicalTrials.gov/show/NCT01149850

Study 318 – Recruiting
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Lymphoma

http://ClinicalTrials.gov/show/NCT00720876

Study 319 – Recruiting
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Urothelial Carcinoma

http://ClinicalTrials.gov/show/NCT01437488

Study 320 – Recruiting
Trial of pIL-12 Electroporation Malignant Melanoma

Melanoma

http://ClinicalTrials.gov/show/NCT01502293

Study 321 – Active, not recruiting
GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

Prostate Cancer

http://ClinicalTrials.gov/show/NCT00122005

Study 322 – Recruiting
Immunization of Patients With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT00793208
Study 323 – Active, not recruiting
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Breast Cancer
http://ClinicalTrials.gov/show/NCT00033514

Study 324 – Recruiting
A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
Squamous Cell Carcinoma
http://ClinicalTrials.gov/show/NCT00660218

Study 325 – Recruiting
S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01668719

Study 326 – Active, not recruiting
Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
Lymphoproliferative Disorder
http://ClinicalTrials.gov/show/NCT00869323

Study 327 – Active, not recruiting
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Melanoma
http://ClinicalTrials.gov/show/NCT01079741

Study 328 – Recruiting
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma

Synovial Sarcoma

http://ClinicalTrials.gov/show/NCT01343043

Study 329 – Recruiting
Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients

HPV-related Head and Neck Cancer

http://ClinicalTrials.gov/show/NCT01493154

Study 330 – Active, not recruiting
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

Metastatic Melanoma

http://ClinicalTrials.gov/show/NCT00626860

Study 331 – Recruiting
Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients

Leukemia

http://ClinicalTrials.gov/show/NCT01756677

Study 332 – Active, not recruiting
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma

Lymphoma

http://ClinicalTrials.gov/show/NCT00244985
Study 333 – Active, not recruiting
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT00947388

Study 334 – Recruiting
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01004991

Study 335 – Recruiting
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Follicular Lymphoma
http://ClinicalTrials.gov/show/NCT01147393

Study 336 – Recruiting
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ NHL
Non-Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT01397591

Study 337 – Active, not recruiting
Universal GM-CSF-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
Lymphoma
http://ClinicalTrials.gov/show/NCT00101101

Study 338 – Recruiting
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Acute Myelogenous Leukemia
Study 339 – Recruiting
High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Melanoma

Study 340 – Active, not recruiting
Study of Repeat Intralodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell, and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma | Follicular Lymphoma | Diffuse Large Cell Lymphoma | Mantle Cell Lymphoma | Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia

Study 341 – Active, not recruiting
Study of Repeat Intralodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Study 342 – Active, not recruiting
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Kidney Cancer

Study 343 – Recruiting
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
Lymphoma
Study 344 – Active, not recruiting
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Head and Neck Cancer
http://ClinicalTrials.gov/show/NCT00423930

Study 345 – Recruiting
Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)
Leukemia
http://ClinicalTrials.gov/show/NCT00840931

Study 346 – Recruiting
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer
http://ClinicalTrials.gov/show/NCT01296035

Study 347 – Active, not recruiting
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
Non-Small Cell Lung Cancer | Head and Neck Cancer
http://ClinicalTrials.gov/show/NCT01528137

Study 348 – Recruiting
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Lung Cancer
http://ClinicalTrials.gov/show/NCT01766739
Study 349 – Active, not recruiting
A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer
Ovarian Cancer | Peritoneal Cancer
http://ClinicalTrials.gov/show/NCT00683241

Study 350 – Recruiting
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Diffuse Large Cell Lymphoma | Mantle Cell Lymphoma | Indolent Non-Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT01479842

Study 351 – Active, not recruiting
Bevacizumab and Docetaxel in Treating Older Patients With Stage III-IV Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01665443

Study 352 – Active, not recruiting
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Leukemia
http://ClinicalTrials.gov/show/NCT00096044

Study 353 – Active, not recruiting
A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
Melanoma
http://ClinicalTrials.gov/show/NCT00746746
Study 354 – Recruiting
Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
Melanoma
http://ClinicalTrials.gov/show/NCT01425749

Study 355 – Recruiting
Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00655850

Study 356 – Active, not recruiting
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
Leukemia
http://ClinicalTrials.gov/show/NCT00415857

Study 357 – Active, not recruiting
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01557959

Study 358 – Recruiting
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01472562
Study 359 – Recruiting
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
Leukemia | Myelodysplastic Syndrome
http://ClinicalTrials.gov/show/NCT00672165

Study 360 – Recruiting
Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01349569

Study 361 – Recruiting
Umbilical Cord Transplantation for the Elderly Population
Hematologic Malignancies
http://ClinicalTrials.gov/show/NCT01484470

Study 362 – Not yet recruiting
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
Diffuse Large Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01539174

Study 363 – Recruiting
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL
Chronic Lymphocytic Leukemia
Study 364 – Active, not recruiting
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIIC or Stage IV Melanoma
Malignant Melanoma

http://ClinicalTrials.gov/show/NCT00471887

Study 365 – Recruiting
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Malignant Melanoma

http://ClinicalTrials.gov/show/NCT01211262

Study 366 – Recruiting
Pilot Study of IFN α2b for Melanoma Patients
Melanoma

http://ClinicalTrials.gov/show/NCT00871533

Study 367 – Recruiting
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
Malignant Melanoma | Neoplasm Metastasis

http://ClinicalTrials.gov/show/NCT00116363

Study 368– Active, not recruiting
Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies
Non-hematologic Malignancies

http://ClinicalTrials.gov/show/NCT00641160

Study 369 – Recruiting
MSB0010718C in Solid Tumors
Solid Tumors

http://ClinicalTrials.gov/show/NCT01772004

Study 370 – Active, not recruiting
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT01336933

Study 371 – Active, not recruiting
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Breast Cancer
http://ClinicalTrials.gov/show/NCT00095706

Study 372 – Recruiting
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
Melanoma
http://ClinicalTrials.gov/show/NCT01092728

Study 373 – Recruiting
A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
Gastrointestinal Adenocarcinomas
http://ClinicalTrials.gov/show/NCT01284231

Study 374 – Active, not recruiting
Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma
Malignant Glioma
http://ClinicalTrials.gov/show/NCT00591058
Study 375 – Enrolling by invitation
A Rollover Protocol for Subjects Previously Treated With AGS-003
Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01482949

Study 376 – Recruiting
Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors
Malignant Solid Tumors
http://ClinicalTrials.gov/show/NCT01632696

Study 377 – Active, not recruiting
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
Gastric Cancer | Stomach Cancer
http://ClinicalTrials.gov/show/NCT00857246

Study 378 – Recruiting
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non-Small Cell Lung Cancer
Lung Cancer
http://ClinicalTrials.gov/show/NCT01263782

Study 379 – Active, not recruiting
Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer
Colorectal Cancer | Neoplasm Metastasis
http://ClinicalTrials.gov/show/NCT00444678

Study 380 – Recruiting
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

http://ClinicalTrials.gov/show/NCT01091259

Study 381 – Recruiting
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Breast Cancer

http://ClinicalTrials.gov/show/NCT01419197

Study 382 – Recruiting
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Breast Cancer

http://ClinicalTrials.gov/show/NCT00999804

Study 383 – Recruiting
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

Midline Carcinoma

http://ClinicalTrials.gov/show/NCT01587703
Study 384 – Recruiting
Bevacizumab Beyond Progression (BBP)

Malignant Glioma | Grade 4 Malignant Glioma | Glioblastoma | Gliosarcoma
http://ClinicalTrials.gov/show/NCT01740258

Cardiovascular Disease – 34 Active Clinical trials

Study 1 – Recruiting
The Fibrin Pad Cardiovascular Study
Cardiovascular Disease
http://ClinicalTrials.gov/show/NCT01681030

Study 2 – Recruiting
A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects
Hypercholesterolemia
http://ClinicalTrials.gov/show/NCT01720537

Study 3 – Recruiting
Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)
Intermittent Claudication | Peripheral Artery Disease
http://ClinicalTrials.gov/show/NCT01679990

Study 4 – Recruiting
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia
Critical Limb Ischemia
http://ClinicalTrials.gov/show/NCT01410331

Study 5 – Active, not recruiting
A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Heart Failure
Heart Failure
http://ClinicalTrials.gov/show/NCT00721045

Study 6 – Recruiting
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.

Ischemic Heart Failure
http://ClinicalTrials.gov/show/NCT01643590
Study 7 – Active, not recruiting
To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction
Congestive Heart Failure
http://ClinicalTrials.gov/show/NCT00526253

Study 8 – Recruiting
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
Chronic Myocardial Ischemia | Refractory Angina Pectoris | (Advanced) Coronary Heart Disease
http://ClinicalTrials.gov/show/NCT01508910

Study 9 – Active, not recruiting
A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients
Stable Atherothrombotic Disease
http://ClinicalTrials.gov/show/NCT01499420

Study 10 – Recruiting
A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
Acute Peripheral Arterial Occlusion
http://ClinicalTrials.gov/show/NCT01222117

Study 11 – Recruiting
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
Homozgygous Familial Hypercholesterolemia
http://ClinicalTrials.gov/show/NCT01588496

Study 12 – Recruiting
Study to Examine the Effects of MultiStem in Ischemic Stroke
Ischemic Stroke
http://ClinicalTrials.gov/show/NCT01436487

Study 13 – Not yet recruiting
Study to Assess the Efficacy and Safety of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Heart, Using an Catheter Delivery System
Ischemic Cardiomyopathy
http://ClinicalTrials.gov/show/NCT00626314

Study 14 – Active, not recruiting
Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins
Atherosclerosis
http://ClinicalTrials.gov/show/NCT01587365

Study 15 – Not yet recruiting
Patients With Intermittent Claudication Injected With ALDH Bright Cells
Peripheral Arterial Disease | Intermittent Claudication
http://ClinicalTrials.gov/show/NCT01774097

Study 16 – Recruiting
A Study of Modified Stem Cells in Stable Ischemic Stroke
Chronic Ischemic Stroke
http://ClinicalTrials.gov/show/NCT01287936

Study 17 – Recruiting
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
Myocardial Infarction
http://ClinicalTrials.gov/show/NCT01458405

Study 18 – Recruiting
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke
Ischemic Stroke
http://ClinicalTrials.gov/show/NCT01297413

Study 19 – Active, not recruiting
Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD)
Peripheral Arterial Disease (PAD)|Claudication
http://ClinicalTrials.gov/show/NCT00390767

Study 20 – Recruiting
Feasibility Study of BMAC Enhanced CABG
Congestive Heart Failure
http://ClinicalTrials.gov/show/NCT01074099

Study 21 – Recruiting
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Hereditary Angioedema
http://ClinicalTrials.gov/show/NCT01095510

Study 22 – Recruiting
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Ischemic Stroke
http://ClinicalTrials.gov/show/NCT01273337
Study 23 – Active, not recruiting
Study to Assess the Tolerability and Efficacy of AMG 145 in Patients With Hypercholesterolemia Unable to Tolerate an Effective Dose of a Statin.
Hyperlipidemia
http://ClinicalTrials.gov/show/NCT01375764

Study 24 – Recruiting
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction
ST Segment Elevation Myocardial Infarction
http://ClinicalTrials.gov/show/NCT01495364

Study 25 – Recruiting
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
Ischemic Dilated Cardiomyopathy
http://ClinicalTrials.gov/show/NCT01670981

Study 26 – Recruiting
An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
Critical Limb Ischemia
http://ClinicalTrials.gov/show/NCT01483898

Study 27 – Active, not recruiting
Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
Dilated Cardiomyopathy
http://ClinicalTrials.gov/show/NCT01020968

Study 28 – Not yet recruiting
Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia
Peripheral Vascular Diseases
http://ClinicalTrials.gov/show/NCT01558908

Study 29 – Not yet recruiting
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
ST Segment Elevation Myocardial Infarction | Allogeneic Mesenchymal Bone Marrow Cells
http://ClinicalTrials.gov/show/NCT01770613

Study 30 – Active, not recruiting
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke
Ischemic Stroke
http://ClinicalTrials.gov/show/NCT01310114

Study 31 – Active, not recruiting
Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI) Heart Disease | Blocked Arteries | Coronary Ischemia | Coronary Disease | Coronary Artery Disease | Coronary Atherosclerosis
http://ClinicalTrials.gov/show/NCT00790764

Study 32 – Not yet recruiting
IVIG in Acute Ischemic Stroke: A Pilot Study
Ischemic Stroke
http://ClinicalTrials.gov/show/NCT01628055
Study 33 – Active, not recruiting
Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)
Coronary Artery Disease
http://ClinicalTrials.gov/show/NCT00314366

Study 34 – Recruiting
Evaluating a Heart Magnetic Resonance Imaging (MRI) Procedure and the Effect of Fish Oil Supplementation in People Who Have Recently Had a Heart Attack (The PROSPECT-CMR Study)
Myocardial Infarction
http://ClinicalTrials.gov/show/NCT00729430

Diabetes – 5 Active Clinical Trials

Study 1 – Active, not recruiting
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Type I Diabetes
http://ClinicalTrials.gov/show/NCT01308437

Study 2 – Active, not recruiting
Safety Study of Subcutaneously Injected Prandial INSULIN-PH20 NP Compared to Insulin Analog Injection in Patients With Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
http://ClinicalTrials.gov/show/NCT00883558
Study 3 – Active, not recruiting
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
Type 2 Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT00838903

Study 4 – Active, not recruiting
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT00838916

Study 5 – Active, not recruiting
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
Type 2 Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT00839527

**Digestive Disorders – 18 Active Clinical Trials**

Study 1 – Active, not recruiting
A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (CR014179)
Ulcerative Colitis
http://ClinicalTrials.gov/show/NCT00488631

Study 2 – Recruiting
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Crohn's Disease
http://ClinicalTrials.gov/show/NCT01545050

Study 3 – Recruiting
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
Colitis, Ulcerative
http://ClinicalTrials.gov/show/NCT01284062

Study 4 – Recruiting
B0151003 Open-Label Extension Study
Crohn's Disease
http://ClinicalTrials.gov/show/NCT01345318

Study 5 – Recruiting
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Crohn's Disease
http://ClinicalTrials.gov/show/NCT01576471

Study 6 – Active, not recruiting
Gender-Stratified Safety and Immunogenicity Study
Diarrhea
http://ClinicalTrials.gov/show/NCT01067781

Study 7 – Active, not recruiting
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
Short Bowel Syndrome
http://ClinicalTrials.gov/show/NCT00930644

Study 8 – Active, not recruiting
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Crohn's Disease
http://ClinicalTrials.gov/show/NCT01190839

Study 9 – Active, not recruiting
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn’s Disease
Crohn’s Disease
http://ClinicalTrials.gov/show/NCT00552344

Study 10 – Not Yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn’s Disease
Crohn’s Disease
http://ClinicalTrials.gov/show/NCT01769755

Study 11 – Active, not recruiting
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn’s Disease
Crohn’s Disease
http://ClinicalTrials.gov/show/NCT01155362

Study 12 – Active, not recruiting
Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
Crohn's Disease
http://ClinicalTrials.gov/show/NCT00686374
Study 13 – Recruiting
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
http://ClinicalTrials.gov/show/NCT01694485

Study 14 – Active, not recruiting
Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Crohn's Disease
http://ClinicalTrials.gov/show/NCT01434693

Study 15 – Active, not recruiting
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
Ulcerative Colitis
http://ClinicalTrials.gov/show/NCT00573794

Study 16 – Recruiting
The EVICEL® Gastrointestinal Study
Gastrointestinal Diseases
http://ClinicalTrials.gov/show/NCT01589822

Study 17 – Recruiting
Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq®) in Infants With Short Bowel Syndrome
Short Bowel Syndrome
http://ClinicalTrials.gov/show/NCT00767364

Study 18 – Recruiting
Autologous Stem Cell Transplantation for Crohn's Disease
Crohn's Disease
http://ClinicalTrials.gov/show/NCT00692939

**Eye Disorders – 14 Active Clinical Trials**

Study 1 – Recruiting
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
*Age-Related Macular Degeneration*
http://ClinicalTrials.gov/show/NCT01024998
Study 2 – Recruiting
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Age-Related Macular Degeneration
http://ClinicalTrials.gov/show/NCT01003691

Study 3 – Recruiting
ESBA1008 Safety, Tolerability and Effects in Wet Age-related Macular Degeneration (AMD) Patients
Exudative Age-related Macular Degeneration
http://ClinicalTrials.gov/show/NCT01304693

Study 4 – Recruiting
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration
Dry Age Related Macular Degeneration
http://ClinicalTrials.gov/show/NCT01344993

Study 5 – Recruiting
Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt’s Macular Dystrophy
Stargardt’s Macular Dystrophy
http://ClinicalTrials.gov/show/NCT01345006

Study 6 – Not yet recruiting
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
Ligneous Conjunctivitis
http://ClinicalTrials.gov/show/NCT01554956

Study 7 – Active, not recruiting
Study of Intravitreal Administration of VEGF Trap-Eye (BAY86-5321) in Patients With Diabetic Macular Edema
Diabetic Macular Edema
http://ClinicalTrials.gov/show/NCT01363440

Study 8 – Not yet recruiting
A Study to Determine the Long Term Safety, Tolerability and Biological Activity of StarGen™ in Patients With Stargardt’s Macular Degeneration
Stargardt’s Disease
http://ClinicalTrials.gov/show/NCT01736592

Study 9 – Active, not recruiting
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration
Neovascular Age Related Macular Degeneration
http://ClinicalTrials.gov/show/NCT00767949

Study 10 – Active, not recruiting
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
Macular Degeneration
http://ClinicalTrials.gov/show/NCT01134055

Study 11 – Active, not recruiting
Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)
Idiopathic Juxtafoveal Telangiectasia
http://ClinicalTrials.gov/show/NCT01327911
Study 12 – Recruiting
A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration
Age-related Macular Degeneration
http://ClinicalTrials.gov/show/NCT01226628

Study 13 – Recruiting
Pilot Study of X-82 in Patients With Wet AMD
Exudative Macular Degeneration
http://ClinicalTrials.gov/show/NCT01674569

Study 14 – Recruiting
Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser
Diabetic Macular Edema
http://ClinicalTrials.gov/show/NCT00491166

Genetic Disorders – 16 Active Clinical trials

Study 1 – Recruiting
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
Cystic Fibrosis
http://ClinicalTrials.gov/show/NCT01684410
Study 2 – Recruiting
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Cystic Fibrosis
http://ClinicalTrials.gov/show/NCT01695343

Study 3 – Active, not recruiting
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
Fabry Disease
http://ClinicalTrials.gov/show/NCT00701415

Study 4 – Recruiting
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
X-linked Hypophosphatemia
http://ClinicalTrials.gov/show/NCT01340482

Study 5 – Recruiting
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
X-linked Hypophosphatemia
http://ClinicalTrials.gov/show/NCT01571596

Study 6 – Active, not recruiting
Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease
Pompe Disease
http://ClinicalTrials.gov/show/NCT01230801

Study 7 – Not yet recruiting
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
Leber Congenital Amaurosis
http://ClinicalTrials.gov/show/NCT00749957

Study 8 – Active, not recruiting
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
Fabry Disease

http://ClinicalTrials.gov/show/NCT01218659

Study 9 – Active, not recruiting
Safety Study of Replagal® Therapy in Children With Fabry Disease
Fabry Disease

http://ClinicalTrials.gov/show/NCT01363492
Study 10 – Enrolling by invitation
Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease
Fabry Disease
http://ClinicalTrials.gov/show/NCT01124643

Study 11 – Recruiting
Extension Study for Patients Who Have Completed BMN 701 Studies
Pompe Disease
http://ClinicalTrials.gov/show/NCT01435772

Study 12 – Active, not recruiting
Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects
Pelizaeus-Merzbacher Disease
http://ClinicalTrials.gov/show/NCT01005004

Study 13 – Active, not recruiting
Extension Study of Protocol ENB-006-09 -Asfotase Alfa Treatment in Children With Hypophosphatasia
Hypophosphatasia
http://ClinicalTrials.gov/show/NCT01203826

Study 14 – Active, not recruiting
Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD)
Pelizaeus-Merzbacher Disease
http://ClinicalTrials.gov/show/NCT01391637

Study 15– Recruiting
Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases
Lysosomal Storage Diseases

http://ClinicalTrials.gov/show/NCT01003912

Study 16 – Active, not recruiting
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency

Alpha 1-Antitrypsin Deficiency

http://ClinicalTrials.gov/show/NCT00430768
Infectious Diseases – 122 Active Clinical Trials

Study 1 – Recruiting
Consistency Study of GlaxoSmithKline (GSK) Biologicals’ MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.’s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age
Measles, Mumps and Rubella Diseases
http://ClinicalTrials.gov/show/NCT01702428

Study 2 – Active, not recruiting
Consistency & Immunogenicity Study of 3 Lots of GSK’s Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants
Meningitis, Osteomyelitis, Epiglottis, Cellulitis, Haemophilus Influenzae Type B-Related Disease | Pneumonia
http://ClinicalTrials.gov/show/NCT01000974

Study 3 – Active, not recruiting
Immunogenicity of GSKs’ MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
Measles, Mumps, Rubella and Varicella Viruses
http://ClinicalTrials.gov/show/NCT00861744

Study 4 – Recruiting
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Measles, Mumps and Rubella Diseases
http://ClinicalTrials.gov/show/NCT01621802

Study 5 – Recruiting
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Measles, Mumps and Rubella Diseases

http://ClinicalTrials.gov/show/NCT01681992

Study 6 – Active, not recruiting
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

H9N2 Pandemic Influenza

http://ClinicalTrials.gov/show/NCT01659086
Study 7 – Active, not recruiting
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Herpes Zoster in HIV-infected Subjects
http://ClinicalTrials.gov/show/NCT01165203

Study 8 – Active, not recruiting
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 70 Years
Herpes Zoster
http://ClinicalTrials.gov/show/NCT01165229

Study 9 – Active, not recruiting
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years
Herpes Zoster
http://ClinicalTrials.gov/show/NCT01165177

Study 10 – Recruiting
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Herpes Zoster (HZ)
http://ClinicalTrials.gov/show/NCT01610414

Study 11 – Active, not recruiting
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
Pandemic H5N1 Influenza
http://ClinicalTrials.gov/show/NCT01310413

Study 12 – Active, not recruiting
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

Meningococcal Disease

http://ClinicalTrials.gov/show/NCT00718666

Study 13 – Active, not recruiting
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Meningococcal Disease

http://ClinicalTrials.gov/show/NCT00715910
Study 14 – Not yet recruiting
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Herpes Zoster
http://ClinicalTrials.gov/show/NCT01767467

Study 15 – Active, not recruiting
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
Prophylaxis for HPV Infections and Associated Cervical Neoplasia
http://ClinicalTrials.gov/show/NCT00294047

Study 16 – Recruiting
Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
Staphylococcal Infections | Staphylococcal Vaccines | Bacterial Infections
http://ClinicalTrials.gov/show/NCT01643941

Study 17 – Active, not recruiting
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
Staphylococcal Infections | Staphylococcal Vaccines | Bacterial Infections | Staphylococcal Skin Infections
http://ClinicalTrials.gov/show/NCT01364571

Study 18 – Active, not recruiting
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Meningitis | Meningococcal Infection
http://ClinicalTrials.gov/show/NCT00806195

Study 19 – Active, not recruiting
Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine
Genital Herpes Simplex Type 2
http://ClinicalTrials.gov/show/NCT01667341

Study 20 – Active, not recruiting
A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus
Healthy
http://ClinicalTrials.gov/show/NCT01405885
Study 21 – Active, not recruiting
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine (TetraMen-T) in Infants and Toddlers
Meningitis | Meningococcal Infection
http://ClinicalTrials.gov/show/NCT01049035

Study 22 – Active, not recruiting
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1
Influenza (Pandemic)
http://ClinicalTrials.gov/show/NCT01594320

Study 23 – Active, not recruiting
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2
Influenza (Pandemic)
http://ClinicalTrials.gov/show/NCT01596725

Study 24 – Active, not recruiting
RSV-F Vaccine Dose Ranging Study in Young Women
Respiratory Syncytial Virus (RSV)
http://ClinicalTrials.gov/show/NCT01704365

Study 25 – Active, not recruiting
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Clostridium Difficile Infection | Diarrhea
http://ClinicalTrials.gov/show/NCT01230957

Study 26 – Recruiting
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
Clostridium Difficile Associated Disease
http://ClinicalTrials.gov/show/NCT01706367

Study 27 – Active, not recruiting
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
Respiratory Syncytial Virus (RSV)
http://ClinicalTrials.gov/show/NCT01709019

Study 28 – Active, not recruiting
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults
Healthy
http://ClinicalTrials.gov/show/NCT01250795
Study 29 – Recruiting
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Hepatitis C
http://ClinicalTrials.gov/show/NCT01309932

Study 30 – Recruiting
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Pneumococcal Disease
http://ClinicalTrials.gov/show/NCT01545375

Study 31 – Active, not recruiting
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Yellow Fever
http://ClinicalTrials.gov/show/NCT01488890

Study 32 – Active, not recruiting
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Tetanus | Diphtheria | Pertussis | Measles | Polio
http://ClinicalTrials.gov/show/NCT01346293

Study 33 – Recruiting
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 & 3
Hepatitis C Virus (HCV)
http://ClinicalTrials.gov/show/NCT01616524
Study 34 – Active, not recruiting
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
Clostridium Difficile Infection
http://ClinicalTrials.gov/show/NCT01259726

Study 35 – Recruiting
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
Influenza
http://ClinicalTrials.gov/show/NCT01773928
Study 36 – Active, not recruiting
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
**Encephalitis**
[http://ClinicalTrials.gov/show/NCT01047839](http://ClinicalTrials.gov/show/NCT01047839)

Study 37 – Active, not recruiting
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
**Chronic Hepatitis C Infection**
[http://ClinicalTrials.gov/show/NCT01225380](http://ClinicalTrials.gov/show/NCT01225380)

Study 38 – Recruiting
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age
**Vaccines | Meningococcal Vaccines**
[http://ClinicalTrials.gov/show/NCT01461980](http://ClinicalTrials.gov/show/NCT01461980)

Study 39 – Active, not recruiting
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
**Influenza**
[http://ClinicalTrials.gov/show/NCT01712984](http://ClinicalTrials.gov/show/NCT01712984)

Study 40 – Active, not recruiting
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
**Hepatitis C, Chronic**
[http://ClinicalTrials.gov/show/NCT01271790](http://ClinicalTrials.gov/show/NCT01271790)
Study 41 – Active, not recruiting
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17
Vaccines | Meningococcal Vaccines
http://ClinicalTrials.gov/show/NCT01461993

Study 42 – Recruiting
Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses
Influenza
http://ClinicalTrials.gov/show/NCT01756950
Study 43 – Active, not recruiting
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
Influenza
http://ClinicalTrials.gov/show/NCT01612000

Study 44 – Active, not recruiting
Norovirus Bivalent-Vaccine Efficacy Study
Prevention From Norovirus Infection
http://ClinicalTrials.gov/show/NCT01609257

Study 45 – Active, not recruiting
Study to Assess the Effect of Adjuvant and Route of Administration on the Safety, Tolerability, and Immunogenicity of NDV-3 Vaccine Against S.Aureus and Candida Staphylococcal Infections | Yeast Infections | Candidiasis
http://ClinicalTrials.gov/show/NCT01447407

Study 46 – Recruiting
Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
HIV Infections
http://ClinicalTrials.gov/show/NCT01428596

Study 47 – Active, not recruiting
A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)
HIV Infections
http://ClinicalTrials.gov/show/NCT00532974

Study 48 – Recruiting
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027 AM1)
Measles | Mumps | Rubella | Varicella
http://ClinicalTrials.gov/show/NCT01536405

Study 49 – Recruiting
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
HIV Infection

http://ClinicalTrials.gov/show/NCT01069809

Study 50 – Recruiting
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Meningococcal Meningitis

http://ClinicalTrials.gov/show/NCT01148017

Study 51 – Active, not recruiting
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
Meningitis | Meningococcal Meningitis | Meningococcal Infections | Invasive Meningococcal Disease

http://ClinicalTrials.gov/show/NCT01732627

Study 52 – Active, not recruiting
Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.
Influenza

http://ClinicalTrials.gov/show/NCT00216242

Study 53 – Active, not recruiting
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Vaccines, Pneumococcal Conjugate Vaccine

http://ClinicalTrials.gov/show/NCT00980655
Study 54 – Active, not recruiting
Persistence Study of GSK Bio's Tdap Vaccine 1, 3, 5 and 10 Years After Administration as a Single Dose in 106316 Study
Diphtheria | Pertussis | Tetanus
http://ClinicalTrials.gov/show/NCT00489970

Study 55 – Recruiting
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 to 10 Years of Age.
Prevention of Meningococcal Disease
http://ClinicalTrials.gov/show/NCT01682876

Study 56 – Active, not recruiting
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
Influenza
http://ClinicalTrials.gov/show/NCT00521586

Study 57 – Recruiting
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
Hepatitis C Virus
http://ClinicalTrials.gov/show/NCT01598090
Study 58 – Recruiting
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Meningitis, Meningococcal
http://ClinicalTrials.gov/show/NCT01352793

Study 59 – Recruiting
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
Anthrax
http://ClinicalTrials.gov/show/NCT01770743

Study 60 – Active, not recruiting
Bivalent Norovirus Vaccine Study
Gastroenteritis | Infection
http://ClinicalTrials.gov/show/NCT01168401

Study 61 – Not yet recruiting
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
Human Immunodeficiency Virus
http://ClinicalTrials.gov/show/NCT01734850

Study 62 – Recruiting
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Human Papillomavirus Infection | Cervical Neoplasia
http://ClinicalTrials.gov/show/NCT01190176

Study 63 – Active, not recruiting
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
Cholera
http://ClinicalTrials.gov/show/NCT01585181
Study 64 – Active, not recruiting
ACE393-103 Vaccination Challenge Study
Campylobacter Infection
http://ClinicalTrials.gov/show/NCT00859716

Study 65 – Recruiting
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
Meningococcal Disease
http://ClinicalTrials.gov/show/NCT01641042
Study 66 – Recruiting
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
Human Papillomavirus (HPV) Type 16/18 Infections | Cervical Neoplasia
http://ClinicalTrials.gov/show/NCT01190189

Study 67 – Recruiting
Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)
Tuberculosis Infection
http://ClinicalTrials.gov/show/NCT01689831

Study 68 – Recruiting
Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody
Cytomegalovirus Infections
http://ClinicalTrials.gov/show/NCT01594437

Study 69 – Active, not recruiting
Trial of Yellow Fever Inactivated Vaccine
Yellow Fever
http://ClinicalTrials.gov/show/NCT00995865

Study 70 – Active, not recruiting
Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer
Healthy Adult Volunteers
http://ClinicalTrials.gov/show/NCT01354379

Study 71 – Recruiting
Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
Season Influenza
http://ClinicalTrials.gov/show/NCT01688297
Study 72 – Recruiting
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected Vaccinia-Naive Adults
HIV Infections
http://ClinicalTrials.gov/show/NCT01571960

Study 73 – Active, not recruiting
H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers
Influenza A Subtype H5N1 Infection
http://ClinicalTrials.gov/show/NCT01657929
Study 74 – Recruiting
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
Dengue Fever
http://ClinicalTrials.gov/show/NCT01666652

Study 75 – Active, not recruiting
Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease
Dengue Disease | Dengue Fever
http://ClinicalTrials.gov/show/NCT01502358

Study 76 – Active, not recruiting
Seasonal Influenza HA DNA Vaccine (VRC) and Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children and Adolescents
Influenza
http://ClinicalTrials.gov/show/NCT01609998

Study 77 – Active, not recruiting
Seasonal Influenza HA DNA (VRC) With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults Ages 18-70 Years
Influenza
http://ClinicalTrials.gov/show/NCT01676402

Study 78 – Active, not recruiting
Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone
Influenza
http://ClinicalTrials.gov/show/NCT01498718

Study 79 – Recruiting
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy

Influenza Viral Infections

http://ClinicalTrials.gov/show/NCT01666782

Study 80 – recruiting
Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

HIV Disease

http://ClinicalTrials.gov/show/NCT01731691

Study 81 – Recruiting
Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy

HIV Infection

http://ClinicalTrials.gov/show/NCT00991224

Study 82 – Active, not recruiting
Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

HIV Infection

http://ClinicalTrials.gov/show/NCT01252641

Study 83 – Active, not recruiting
Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers

Smallpox

http://ClinicalTrials.gov/show/NCT00103584

Study 84 – Active, not recruiting
Study of Daclatasvir and TMC435 for Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C Virus

http://ClinicalTrials.gov/show/NCT01628692
Study 85 – Active, not recruiting
A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001
Influenza Vaccines
http://ClinicalTrials.gov/show/NCT01224262

Study 86 – Recruiting
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Chronic Hepatitis C Virus
http://ClinicalTrials.gov/show/NCT01516918

Study 87 – Recruiting
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
Pandemic H5N1 Influenza
http://ClinicalTrials.gov/show/NCT01766921

Study 88 – Active, not recruiting
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
Chronic Hepatitis C Virus Infection
http://ClinicalTrials.gov/show/NCT01080222

Study 89 – Not yet recruiting
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Pandemic H5N1 Influenza
http://ClinicalTrials.gov/show/NCT01776554

Study 90 – Active, not recruiting
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
Chronic Hepatitis C
http://ClinicalTrials.gov/show/NCT01356160

Study 91 – Active, not recruiting
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Chronic Hepatitis C
http://ClinicalTrials.gov/show/NCT01371578

Study 92 – Active, not recruiting
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Hepatitis C
http://ClinicalTrials.gov/show/NCT01467479

Study 93 – Recruiting
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
Pneumococcal Conjugate Vaccine
http://ClinicalTrials.gov/show/NCT00918580

Study 94 – Not yet recruiting
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults
Pandemic H5N1 Influenza
http://ClinicalTrials.gov/show/NCT01776541

Study 95 – Active, not recruiting
Study on Interleukin-7 (CYT107) in HIV Patients
HIV Infection
http://ClinicalTrials.gov/show/NCT01190111
Study 96 – Recruiting
Ciprofloxacin BioThrax Co-Administration Study
Anthrax
http://ClinicalTrials.gov/show/NCT01753115

Study 97 – Recruiting
A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
Dengue
http://ClinicalTrials.gov/show/NCT01542632

Study 98 – Recruiting
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART
HIV-1 Infection
http://ClinicalTrials.gov/show/NCT01378156

Study 99 – Recruiting
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
HIV-1 Infection
http://ClinicalTrials.gov/show/NCT01712256

Study 100 – Active, not recruiting
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
Japanese Encephalitis
http://ClinicalTrials.gov/show/NCT01246479

Study 101 – Active, not recruiting
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
Chronic Hepatitis B | Chronic Hepatitis C
http://ClinicalTrials.gov/show/NCT01708889

Study 102 – Recruiting
Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
Influenza
http://ClinicalTrials.gov/show/NCT01560793

Study 103 – Active, not recruiting
Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
HIV Infection
http://ClinicalTrials.gov/show/NCT00005002

Study 104 – Recruiting
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
HIV Infection
http://ClinicalTrials.gov/show/NCT01546818

Study 105 – Recruiting
Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum
Seasonal Influenza
http://ClinicalTrials.gov/show/NCT01761123

Study 106 – Active, not recruiting
Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects
Anthrax
http://ClinicalTrials.gov/show/NCT01265745
Study 107 – Recruiting
Immunogenicity of ND1.1 by Delivery Directly to the Ileum
Avian Influenza
http://ClinicalTrials.gov/show/NCT01698060

Study 108 – Recruiting
A Phase 2a Study of GS-6624 in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis
Liver Fibrosis | Hepatitis C | HIV Infection
http://ClinicalTrials.gov/show/NCT01707472

Study 109 – Active, not recruiting
Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults
Influenza
http://ClinicalTrials.gov/show/NCT01302990

Study 110 – Recruiting
Impact of SQ vs IM Administration of DENVax on Safety and Immunogenicity
Dengue
http://ClinicalTrials.gov/show/NCT01728792

Study 111 – Recruiting
Candin Safety & Efficacy Study for the Treatment of Warts
Warts | Human Papilloma Virus
http://ClinicalTrials.gov/show/NCT01757392

Study 112 – Active, not recruiting
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
HIV Infection
http://ClinicalTrials.gov/show/NCT00976404
Study 113 – Recruiting
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
Adenovirus Infection | EBV Infection
http://ClinicalTrials.gov/show/NCT00711035
Study 114 – Recruiting
Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents
Immunosenescence | Shingles
http://ClinicalTrials.gov/show/NCT01262300

Study 115 – Recruiting
Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)
Norovirus Infections
http://ClinicalTrials.gov/show/NCT01435811

Study 116 – Recruiting
Study of Gardasil in Mid-Adult Males (MAM)
Human Papillomavirus
http://ClinicalTrials.gov/show/NCT01432574

Study 117 – Active, not recruiting
Campylobacter Jejuni Challenge Model Development: Dose Ranging Study
Campylobacter Infections
http://ClinicalTrials.gov/show/NCT00434798

Study 118 – Recruiting
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Subjects With Recurrent Genital Herpes
Herpes Simplex Type II
http://ClinicalTrials.gov/show/NCT01687595

Study 119 – Recruiting
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Systemic Sclerosis
http://ClinicalTrials.gov/show/NCT01651143
Study 120 – Recruiting
A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease
Anemia, Sickle Cell
http://ClinicalTrials.gov/show/NCT01597401

Study 121 – Active, not recruiting
Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
HIV Infection
http://ClinicalTrials.gov/show/NCT00131560

Study 122 – Active, not recruiting
The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
HIV Infection
http://ClinicalTrials.gov/show/NCT00005120

Musculoskeletal Disorders/Arthritis – 33 Active clinical Trials
— Rheumatoid Arthritis is listed under Autoimmune Disorders —

Study 1 – Recruiting
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
Psoriatic Arthritis
http://ClinicalTrials.gov/show/NCT01490450

Study 2 – Active, not recruiting
Study of Adalimumab in Subjects With Axial Spondyloarthritis
Axial Spondyloarthritis

http://ClinicalTrials.gov/show/NCT00939003

Study 3 – Active, not recruiting
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Psoriatic Arthritis

http://ClinicalTrials.gov/show/NCT01392326

Study 4 – Active, not recruiting
Study of Adalimumab in Subjects With Peripheral Spondyloarthritis

Peripheral Spondyloarthritis

http://ClinicalTrials.gov/show/NCT01064856

Study 5 – Active, not recruiting
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion

Degenerative Disc Disease | Degenerative Spondylolisthesis | Spinal Stenosis

http://ClinicalTrials.gov/show/NCT00996073

Study 6 – Active, not recruiting
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Spondyloarthropathies

http://ClinicalTrials.gov/show/NCT01087762

Study 7 – Active, not recruiting
A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density
Low Bone Mineral Density | Osteopenia | Osteoporosis

http://ClinicalTrials.gov/show/NCT00515463

Study 8 – Active, not recruiting
Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Chronic Discogenic Lumbar Back Pain
Degenerative Disc Disease
http://ClinicalTrials.gov/show/NCT01290367

Study 9 – Active, not recruiting
Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
Psoriatic Arthritis
http://ClinicalTrials.gov/show/NCT01087788

Study 10 – Recruiting
BOTOX® Treatment in Pediatric Upper Limb Spasticity
Muscle Spasticity
http://ClinicalTrials.gov/show/NCT01603602

Study 11 – Recruiting
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee.
Osteoarthritis
http://ClinicalTrials.gov/show/NCT01668511

Study 12 – Recruiting
BOTOX® Treatment in Pediatric Lower Limb Spasticity
Muscle Spasticity
http://ClinicalTrials.gov/show/NCT01603628

Study 13 – Not yet recruiting
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

http://ClinicalTrials.gov/show/NCT01649375

Study 14 – Recruiting
Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects
Osteoarthritis | Degenerative Traumatic Injury

http://ClinicalTrials.gov/show/NCT01733186

Study 15 – Active, not recruiting
Neocartilage Implant Phase III Trial
Articular Cartilage Disorder

http://ClinicalTrials.gov/show/NCT01400607

Study 16 – Recruiting
Confirmatory Study of NeoCart in Knee Cartilage Repair
Cartilage Defects of the Femoral Condyle

http://ClinicalTrials.gov/show/NCT01066702

Study 17 – Recruiting
A Study in Older Participants Who Have Fallen and Have Muscle Weakness
Muscle Weakness

http://ClinicalTrials.gov/show/NCT01604408

Study 18 – Active, not recruiting
Comparison of BioCart™II With Microfracture for Treatment of Cartilage Defects of the Femoral Condyle
Symptomatic Cartilage Defects of the Femoral Condyle

http://ClinicalTrials.gov/show/NCT00729716
Study 19 – Active, not recruiting
NeoCart Phase 2 Clinical Trial
Articular Cartilage Damage
http://ClinicalTrials.gov/show/NCT00548119

Study 20 – Active, not recruiting
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis
Ankylosing Spondylitis
http://ClinicalTrials.gov/show/NCT01109940

Study 21 – Active, not recruiting
Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
Osteoarthritis, Knee
http://ClinicalTrials.gov/show/NCT01221441

Study 22 – Active, not recruiting
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy
Cervical Degenerative Disc Disease | Degenerative Spondylolisthesis | Spinal Stenosis
http://ClinicalTrials.gov/show/NCT01097486

Study 23 – Recruiting
An Open-label Extension Study With Canakinumab on the Treatment and Prevention of Gout Flares up to 3 Years
Chronic Gouty Arthritis
http://ClinicalTrials.gov/show/NCT01470989

Study 24 – Active, not recruiting
Safety and Efficacy Study of Intravenous Uricase-PEG 20
Gout | Hyperuricemia
http://ClinicalTrials.gov/show/NCT01021241

Study 25 – Recruiting
Safety and Efficacy Study of Intramuscular Uricase-PEG 20
Gout | Hyperuricemia
http://ClinicalTrials.gov/show/NCT01038947

Study 26 – Recruiting
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
Muscle Spasticity
http://ClinicalTrials.gov/show/NCT01603615

Study 27 – Recruiting
BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity
Muscle Spasticity
http://ClinicalTrials.gov/show/NCT01603641

Study 28 – Recruiting
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Muscle Spasticity
http://ClinicalTrials.gov/show/NCT01575054

Study 29 – Recruiting
A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo
Degenerative Disc Disease
http://ClinicalTrials.gov/show/NCT01771471

Study 30 – Active, not recruiting
Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

Alveolar Bone Defects
http://ClinicalTrials.gov/show/NCT00755911

Study 31 – Recruiting
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
Osteoarthritis
http://ClinicalTrials.gov/show/NCT01683396

Study 32 – Recruiting
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
Psoriatic Arthritis
http://ClinicalTrials.gov/show/NCT01695239

Study 33 – Recruiting
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Systemic Sclerosis
http://ClinicalTrials.gov/show/NCT01670565

Neurological Disorders – 18 Active Clinical Trials

Study 1 – Active, not recruiting
Study Evaluating ACC-001 in Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT00498602

Study 2 – Active, not recruiting
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01097096

Study 3 – Active, not recruiting
NP2 Enkephalin For Treatment of Intractable Cancer Pain
Intractable Pain | Neoplasms
http://ClinicalTrials.gov/show/NCT01291901

Study 4 – Active, not recruiting
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01227564

Study 5 – Recruiting
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Chronic Inflammatory Demyelinating Polyneuropathy | Polyradiculoneuropathy
http://ClinicalTrials.gov/show/NCT01545076

Study 6 – Recruiting
Phase 3 IGIV, 10% in Alzheimer’s Disease
Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01524887

Study 7 – Recruiting
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
Migraine Disorders
http://ClinicalTrials.gov/show/NCT01662492
Study 8 – Active, not recruiting
Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System
Back Pain | Chronic Low Back Pain | Internal Disc Disruption | Degenerative Disc Disease
http://ClinicalTrials.gov/show/NCT01011816

Study 9 – Active, not recruiting
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Idiopathic Parkinson's Disease
http://ClinicalTrials.gov/show/NCT00985517

Study 10 – Active, not recruiting
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
Alzheimer's Disease
http://ClinicalTrials.gov/show/NCT01284387

Study 11 – Active, not recruiting
Safety Study of GRNOPC1 in Spinal Cord Injury
Spinal Cord Injury
http://ClinicalTrials.gov/show/NCT01217008

Study 12 – Active, not recruiting
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Adhesive Capsulitis | Frozen Shoulder
http://ClinicalTrials.gov/show/NCT01483963

Study 13 – Active, not recruiting
Gene Transfer for Cancer Pain
Cancer Pain
http://ClinicalTrials.gov/show/NCT00804076
Study 14 – Recruiting
Safety, Efficacy and Pharmacokinetics of ALD403
Migraine
http://ClinicalTrials.gov/show/NCT01772524

Study 15 – Active, not recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers
Migraine Disorders
http://ClinicalTrials.gov/show/NCT01511497

Study 16 – Active, not recruiting
Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury
Spinal Cord Injury
http://ClinicalTrials.gov/show/NCT01162915

Study 17 – Active, not recruiting
Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
http://ClinicalTrials.gov/show/NCT01082653

Study 18 – Recruiting
Title Spinocerebellar Ataxia
Spinocerebellar Ataxia Type 3
http://ClinicalTrials.gov/show/NCT01350440

Respiratory Diseases – 8 Active Clinical trials
Study 1 – Recruiting
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
http://ClinicalTrials.gov/show/NCT01678807

Study 2 – Active, not recruiting
A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
http://ClinicalTrials.gov/show/NCT01448850

Study 3 – Recruiting
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
http://ClinicalTrials.gov/show/NCT01629667

Study 4 – Active, not recruiting
Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies
Allergic Rhinitis
http://ClinicalTrials.gov/show/NCT00599872

Study 5 – Recruiting
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
Moderate to Severe Allergic Asthma
http://ClinicalTrials.gov/show/NCT01673672

Study 6 – Recruiting
A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid
Allergic Rhinoconjunctivitis
http://ClinicalTrials.gov/show/NCT01707069

Study 7 – Recruiting
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
Moderate-to-Severe Asthma
http://ClinicalTrials.gov/show/NCT01603277

Study 8 – Recruiting
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
http://ClinicalTrials.gov/show/NCT01266135

Skin Diseases – 15 Active Clinical Trials
Skin cancer clinical trials are listed under Cancer

Study 1 – Recruiting
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
http://ClinicalTrials.gov/show/NCT01468207

Study 2 – Recruiting
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
http://ClinicalTrials.gov/show/NCT01468233
Study 3 – Active, not recruiting
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
Moderate to Severe Plaque-type Psoriasis
http://ClinicalTrials.gov/show/NCT01406938

Study 4 – Recruiting
Evaluation of CureXcell™ in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes
Lower Extremity Chronic Ulcers in Diabetics
http://ClinicalTrials.gov/show/NCT01421966

Study 5 – Recruiting
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
Venous Leg Ulcers
http://ClinicalTrials.gov/show/NCT01656889

Study 6 – Recruiting
Study of ACCS (Amnion-derived Cellular Cytokine Solution) in Diabetic Subjects With Deep Burns Managed With Skin Grafts
Deep Burns in Subjects With Diabetes
http://ClinicalTrials.gov/show/NCT01715012

Study 7 – Recruiting
Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery
Scar Formation
http://ClinicalTrials.gov/show/NCT01053897

Study 8 – Recruiting
A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing

Epidermolysis Bullosa

http://ClinicalTrials.gov/show/NCT01749306

Study 9 – Active, not recruiting
StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
Skin Wound | Burns | Infection Related Wound | Trauma-related Wound

http://ClinicalTrials.gov/show/NCT01437852

Study 10 – Active, not recruiting
A Study in Participants With Moderate to Severe Psoriasis
Psoriasis

http://ClinicalTrials.gov/show/NCT01107457

Study 11 – Recruiting
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
Hidradenitis Suppurativa

http://ClinicalTrials.gov/show/NCT01635764

Study 12 – Recruiting
Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents
Contact Dermatitis

http://ClinicalTrials.gov/show/NCT01518348

Study 13 – Not yet recruiting
Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging
Intrinsic Aging of Skin | Chronic Effect of Ultraviolet Radiation on Normal Skin | Dermatologic Disorders
http://ClinicalTrials.gov/show/NCT01771679

Study 14 – Recruiting
Study of Amnion-derived Cellular Cytokine Solution (ACCS) Versus Saline in Treating Skin Irritation From Radiation
Radiation-induced Dermatitis

http://ClinicalTrials.gov/show/NCT01714973

Study 15 – Recruiting
Use of Botulinum Toxin to Treat Psoriasis
Psoriasis Vulgaris

http://ClinicalTrials.gov/show/NCT00816517

Transplantation – 5 Active Clinical trials

Study 1 – Active, not recruiting
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
Acute GvHD

http://ClinicalTrials.gov/show/NCT01530256

Study 2 – Recruiting
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
GVHD | Adult Acute Myeloid Leukemia | Acute Lymphoid Leukemia | Myelodysplastic Syndrome

http://ClinicalTrials.gov/show/NCT01295710
Study 3 – Recruiting
A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection
Graft Rejection
http://ClinicalTrials.gov/show/NCT01147302

Study 4 – Active, not recruiting
Visilizumab in Treating Patients With Graft-Versus-Host Disease Following Donor Stem Cell Transplantation
Graft Versus Host Disease
http://ClinicalTrials.gov/show/NCT00042744

Study 5 – Recruiting
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
Kidney Transplantation
http://ClinicalTrials.gov/show/NCT01134510

Other – 49 Active Clinical trials

Study 1 – Recruiting
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
Peanut Allergy
http://ClinicalTrials.gov/show/NCT01675882

Study 2 – Recruiting
Study to Evaluate the Safety and Efficacy of Dermal Injections of JVS-100 Given to Adults Receiving Median Sternotomy
Median Sternotomy
http://ClinicalTrials.gov/show/NCT01657045
Study 3 – Recruiting
A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers
Healthy
http://ClinicalTrials.gov/show/NCT01740609

Study 4 – Recruiting
A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects
Healthy
http://ClinicalTrials.gov/show/NCT01616277
Study 5 – Recruiting
GS-6624 in the Treatment of Cirrhosis Due to NASH  
Non-Alcoholic Steatohepatitis (NASH)  
http://ClinicalTrials.gov/show/NCT01672879

Study 6 – Recruiting
A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment  
Chronic Kidney Disease | Chronic Renal Failure  
http://ClinicalTrials.gov/show/NCT01473407

Study 7 – Enrolling by invitation
Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (Study P06031)  
Infertility  
http://ClinicalTrials.gov/show/NCT01146418

Study 8 – Recruiting
A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment  
Chronic Renal Failure | Chronic Kidney Disease  
http://ClinicalTrials.gov/show/NCT01473420

Study 9 – Recruiting
A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects  
Acute Kidney Injury  
http://ClinicalTrials.gov/show/NCT01602328

Study 10 – Not yet recruiting
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers $> 12 \text{ cm}^2$ to $\leq 36 \text{ cm}^2$

**Venous Leg Ulcers**
http://ClinicalTrials.gov/show/NCT01737762

Study 11 – Not yet recruiting

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

**Lupus Nephritis**
http://ClinicalTrials.gov/show/NCT01714817
Study 12 – Recruiting
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Overactive Bladder
http://ClinicalTrials.gov/show/NCT00439140

Study 13 – Active, not recruiting
Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery
Kidney Tubular Necrosis, Acute
http://ClinicalTrials.gov/show/NCT00733876

Study 14 – Active, not recruiting
Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in Chronic Kidney Disease (CKD) Patients
Chronic Kidney Disease
http://ClinicalTrials.gov/show/NCT00985426

Study 15 – Recruiting
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers
Healthy
http://ClinicalTrials.gov/show/NCT01710826

Study 16 – Active, not recruiting
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
Overactive Bladder
http://ClinicalTrials.gov/show/NCT00876447

Study 17 – Recruiting
Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

**Methamphetamine Abuse**

http://ClinicalTrials.gov/show/NCT01603147

Study 18 – Recruiting
A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GI-13020 at Various Dose Levels and Regimens in Healthy Adults.

**Healthy Volunteers**

http://ClinicalTrials.gov/show/NCT01779505

Study 19 – Active, not recruiting
Efficacy of NicVAX in Smokers Who Want to Quit Smoking

**Smoking Cessation**

http://ClinicalTrials.gov/show/NCT00318383

Study 20 – Active, not recruiting
Improving the Efficacy of Anti-Nicotine Immunotherapy

**Nicotine Dependence**

http://ClinicalTrials.gov/show/NCT01280968

Study 21– Recruiting
Open-Label Study of Asfotase Alfa (ENB-0040) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

**Hypophosphatasia**

http://ClinicalTrials.gov/show/NCT01176266

Study 22 – Recruiting
A Phase 3 Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

**Chronic Renal Failure Requiring Hemodialysis**

http://ClinicalTrials.gov/show/NCT01628107
Study 23 – Active, not recruiting
Tolerability and Safety of Immune Globulin Subcutaneous Solution and rHuPH20 in Primary Immunodeficiency Diseases (PID)
Primary Immunodeficiency Diseases
http://ClinicalTrials.gov/show/NCT01175213

Study 24 – Recruiting
A Phase 3 Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment
Chronic Renal Failure Requiring Hemodialysis
http://ClinicalTrials.gov/show/NCT01628120

Study 25 – Recruiting
Study to Assess the Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures
Dupuytren's Contracture
http://ClinicalTrials.gov/show/NCT01674634

Study 26 – Active, not recruiting
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)
Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness
http://ClinicalTrials.gov/show/NCT01669746
Study 27 – Recruiting
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
Urea Cycle Disorders
http://ClinicalTrials.gov/show/NCT01195753

Study 28 – Recruiting
A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
Phenylketonuria
http://ClinicalTrials.gov/show/NCT01560286

Study 29 – Active, not recruiting
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)
Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness
http://ClinicalTrials.gov/show/NCT01451190

Study 30 – Active, not recruiting
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)
Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness
http://ClinicalTrials.gov/show/NCT01451125

Study 31 – Active, not recruiting
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)
Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness
http://ClinicalTrials.gov/show/NCT01451138

Study 32 – Active, not recruiting
Extension Study of Protocol ENB-002-08 - Asfotase Alfa Treatment in Severely Affected Infants and Young Children With Hypophosphatasia (HPP)

Hypophosphatasia
[http://ClinicalTrials.gov/show/NCT01205152](http://ClinicalTrials.gov/show/NCT01205152)

Study 33 – Active, not recruiting
Administration of Two Injections for Multiple Dupuytren's Contractures
Dupuytren's Contracture
[http://ClinicalTrials.gov/show/NCT01407068](http://ClinicalTrials.gov/show/NCT01407068)

Study 34 – Active, not recruiting
Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil
Bilateral Ovarian Disease
[http://ClinicalTrials.gov/show/NCT00544310](http://ClinicalTrials.gov/show/NCT00544310)

Study 35 – Active, not recruiting
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)
Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness
[http://ClinicalTrials.gov/show/NCT01451112](http://ClinicalTrials.gov/show/NCT01451112)

Study 36 – Not yet recruiting
Phase 1b Study Investigating Safety & Immunogenicity of DENVax Given Intradermally by Needle or Needle Free PharmaJet Injector
Normal Healthy Adult
[http://ClinicalTrials.gov/show/NCT01765426](http://ClinicalTrials.gov/show/NCT01765426)

Study 37 – Active, not recruiting
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness
http://ClinicalTrials.gov/show/NCT01451151

Study 38 – Active, not recruiting
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)
Androgenetic Alopecia | Male Pattern Baldness | Female Pattern Baldness

http://ClinicalTrials.gov/show/NCT01451177

Study 39 – Active, not recruiting
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Edematous Fibrosclerotic Panniculopathy|Cellulite

http://ClinicalTrials.gov/show/NCT01518907

Study 40 – Active, not recruiting
Pilot Study of GS-6624 in the Treatment of Liver Fibrosis
Liver Fibrosis

http://ClinicalTrials.gov/show/NCT01452308

Study 41 – Not yet recruiting
A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Overactive Bladder | Urinary Incontinence

http://ClinicalTrials.gov/show/NCT01767519
Study 42 – Active, not recruiting
Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure
Hematopoietic Syndrome Due to Acute Radiation Syndrome
http://ClinicalTrials.gov/show/NCT01742221

Study 43 – Active, not recruiting
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Overactive Bladder | Urinary Incontinence
http://ClinicalTrials.gov/show/NCT00915525

Study 44 – Not yet recruiting
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Acute Alcoholic Hepatitis
http://ClinicalTrials.gov/show/NCT01471028

Study 45 – Not yet recruiting
Efficacy of Iocide Oral Rinse Against Gingival Inflammation
Gingivitis
http://ClinicalTrials.gov/show/NCT01782170

Study 46 – Active, not recruiting
Rituximab + Immune Globulin Intravenous (IVIG) for Desensitization
End Stage Renal Disease
http://ClinicalTrials.gov/show/NCT01178216

Study 47 – Active, not recruiting
Mepolizumab As a Steroid-Sparing Treatment Option in the Churg Strauss Syndrome
Churg Strauss Syndrome
http://ClinicalTrials.gov/show/NCT00527566
Study 48 – Not yet recruiting
A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty
Rhinoplasty
http://ClinicalTrials.gov/show/NCT01684020

Study 49 – Recruiting
Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis
Urinary Incontinence | Multiple Sclerosis
http://ClinicalTrials.gov/show/NCT01600716